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CHAPTER-1 
 
INTRODUCTION 
 
 
1. GENERAL INTRODUCTION
1
 
Oral administration is the most popular route due to ease of ingestion, pain 
avoidance, versatility (to accommodate various types of drug candidates) and most 
importantly, patient compliance. Also, solid oral delivery systems do not require 
sterile conditions and are, therefore, less expensive to manufacture. A vast variety of 
pharmaceutical research is directed at developing new dosage forms for oral 
administration. Most of these efforts have focused on either formulating novel drug 
delivery systems or increasing the patient compliance. Among the dosage forms 
developed for facilitating ease of medication, the orally disintegrating systems have 
been the favorite of product development scientists. In similar fashion the oral cavity 
is highly acceptable by patients, the mucosa is relatively permeable with rich blood 
supply and virtual lack of langerhans cells makes oral mucosa tolerant to potential 
allergens. 
 
1.1. SOLID DOSAGE FORMS 
Drugs are rarely administered solely as pure chemical substances, but are 
almost given as formulated preparations. The principal objective of dosage form 
design is to achieve a predictable therapeutic response to a drug included in the 
formulation. 
Before a drug substance can be successfully formulated into a dosage form, 
many factors must be considered. These factors can be broadly grouped into                
3 categories
2
,  
 
1. Biopharmaceutical considerations (Factors affecting absorption of drugs) 
2. Drug related factors (Physical and Chemical properties of the drug) 
3. Therapeutic considerations (Disease to be treated and Patient factors) 
Among various orally administered dosage forms (tablets, capsules, syrup, solution 
etc…) the tablet dosage form is the most widely used. 
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Solid dosage form is one type of physical dosage forms mainly administrated 
orally in dry state. Some of the solid dosage forms are shown below
 3
. 
 Tablets 
 Capsules 
 Pills 
 Pastilles 
 Lozenges 
 Cachets or powder 
As these contain a quantity of drug which is given as a single unit they are 
known collectively as solid unit – dosage forms4. 
 
1.1.1. TABLETS 
A tablet is a compressed solid unit dosage form containing medicaments with 
or without excipients. According to the Indian pharmacopoeia, pharmaceutical tablets 
are solid flat or biconvex dishes prepared by compressing a drug or a mixture of 
drugs, with or without diluents
5
. 
They vary in shape and differ greatly in size and weight, depending on the 
amount of medical substance and the intended mode of administration. It is the most 
popular dosage form and 70% of the total medicines are dispensed in the form of 
tablets. Tablets offer advantages over both patients and manufacturers. Tablets are the 
most popular dosage form due to their simplicity and economy of manufacture, 
relative stability and convenience in packaging, shipping and storage. Ease of 
manufacturing, convenience in administration, accurate dosing and stability compared 
to oral liquids, tamper proofness compared to capsules and safety compared to 
parentral dosage forms makes it a popular and versatile dosage form
6
. 
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1.1.1.1. ADVANTAGES OF TABLETS
7
       
The primary potential advantages of tablets are  
 They are the unit dosage forms, which offer the great capabilities of all oral 
dosage forms for the greatest dose precision and the least content variability. 
 The cost is lowest of all oral dosage forms. 
 They are the lightest and most compact of all. 
 They are in general the easiest and cheapest to packaging and shipment. 
 Product identification is potentially the simplest and cheapest, requiring no 
additional processing steps when employing an embossed or monogrammed 
punch face. 
 They may provide the greatest ease of swallowing with the least tendency for 
hang up above the stomach, especially when coated, provided the tablet 
disintegration is not excessively rapid. 
 They lend themselves to certain special release profile products, such as 
enteric or delayed release products. 
 They are better suited to large scale production than with other unit oral 
dosage forms. 
 They have the best combined properties of chemical, mechanical and 
microbiological stability of all the oral forms.  
 
1.1.1.2. DISADVANTAGES OF TABLETS 
Inspite of all these advantages, tablets also possess some disadvantages. This 
includes the following 
 Some drugs resist compression into dense compacts, owing to their 
amorphous nature or flocculent and low density character. 
 Drugs with poor wetting properties, slow dissolution properties, 
intermediate to large dosages, poor absorption in the GIT or any 
combination of these features may be difficult or impossible to formulate 
and manufacture as a tablet. 
 Bitter tasting drugs, drug with obnoxious odor or drugs that are sensitive to 
oxygen or atmospheric moisture may require encapsulation / entrapment 
prior to compression / coating. 
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1.1.1.3. CLASSIFICATION OF TABLETS 
 
a) Classification based on mode of administration 
1) Tablets to be swallowed 
2) Chewable tablets 
3) Tablets used in oral cavity 
a)   Buccal tablets 
b)   Sublingual tablets 
c)   Troches and lozenges 
d)   Dental cones 
4) Tablets administered other than oral route 
a) Implants 
b) Vaginal tablets / suppositories 
 
b) Classification based on drug manufacturing process 
1) Standard compressed tablets 
2) Multiple compressed tablets 
a. Compression – coated tablets 
b.  Layered tablets  
3) Coated tablets 
4) Molded tablets (Tablet triturates) 
 
c) Classification based on drug release profile 
 1) Fast Dissolving tablets 
 2) Immediate Release tablets 
 3) Controlled/ Sustained Release tablets  
4) Delayed Release tablets (Enteric coated tablets) 
 
d) Tablets used to prepare solutions 
a) Effervescent tablets 
b) Dispersible tablets  
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1.1.1.4. TABLET EXCIPIENTS
8
 
 
   The excipients are classified according to the function. They include the following. 
a) Fillers / Diluents 
b) Binders 
c) Disintegrants 
d) Lubricants 
e) Glidants 
f) Anti-adherents / anti-adhesives 
g) Colouring agents 
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The details of the tablet excipients are shown in table: 1 
Table: 1 Tablet Excipients 
Excipient 
category 
Applications Working principle Examples   
Diluents Fillers 
Make up the bulk of 
solid unit dosage 
forms when drug itself 
is inadequate to 
produce the bulk 
Lactose, Directly 
compressible Starches, 
Dextrose, Sorbitol, 
Microcrystalline 
cellulose, Dibasic 
Calcium phosphate 
(dehydrate). 
 
Binders and 
Adhesives 
Impart cohesive 
qualities to powdered 
material. 
Improves free flow 
qualities by 
formulation of 
granules to desired 
hardness and size. 
Acacia, Gelatin, Starch 
paste, Polyvinyl 
pyrrolidone, Glucose, 
Carboxymethyl 
cellulose. 
Lubricants 
Reduce inter-
particular friction, 
prevent adhesion of 
tablet material to the 
surface of dies and 
punches, facilitate 
easy ejection of tablet 
from die cavity and 
improve the rate of 
flow of granules. 
Interpose a film of 
low shear strength  
between the tabletting 
mass and die wall 
Talc, Stearic acid, 
Magnesium stearate, 
Calcium stearate, 
Polyethylene glycol, 
Surfactants, vegetable 
oil. 
Glidants  
Improve flow 
characteristics of 
powder mixture. 
Added in dry state 
prior compression, it 
reduces friction 
between particles 
Colloidal Silicone 
dioxide (Carbosil), 
Asbestos free starch, 
Corn starch. 
Disintegrants 
Facilitate breakup or 
disintegration after 
administration. 
 
Improve disintegrant 
efficacy resulting in 
decreased use levels 
when compared to 
traditional 
disintegrants. 
Function by drawing 
water into the tablet, 
swelling it and 
causing the tablet to 
burst apart 
Starches, Clays, 
Cellulose, Cross linked 
polymers, Modified 
starches such as 
Primogel and Explotab, 
Veegum HV, 
Crosscarmalose, Cross 
Povidone, Sodium 
starch glycolate. 
Superdisintegrants 
Coloring agents 
 ( these must be 
approved and 
certified by FDA) 
Impart aesthetic 
appearance to dosage 
form, disguising off 
color drugs, product 
identification. 
Color is a useful tool 
to help and identify a 
product in its 
manufacturing and 
distribution stages. 
FD and C, D and C 
dyes and lakes. 
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1.1.1.5. TABLET MANUFACTURING PROCESS
9
 
An outline of the various steps involved in the manufacturing of tablets by 
different methods is mentioned below in Table: 2 
 
Table: 2 Tablet Manufacturing Process 
Wet Granulation Dry Granulation Direct Compression 
 Milling of drugs and 
excipients 
Milling of drugs and 
excipients 
Milling of drugs and 
excipients 
Mixing of milled products Mixing of milled products 
Mixing of milled 
products 
Preparation of the binder 
solution 
Compression into large hard 
tablets called slugs 
Tablet compression 
Mixing binder solution with 
powder mixture to form wet 
mass 
Screening of slugs - 
Coarse screening of wet 
mass  
Mixing with lubricant and 
disintegrating agent 
- 
Drying moist granules Tablet compression - 
Screening dry granules with 
lubricant and disintegrant 
- - 
Mixing Screened granules 
with lubricant and 
disintegrant 
- - 
Tablet compression - - 
 
The various process involved in the manufacturing of tablet are, 
 Mixing 
 Granulation 
 Drying 
 Milling  
 Compression 
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 Mixing
7 
 Almost every pharmaceutical product contains more than one component and 
this necessitates mixing or blending stages in their manufacturing process. 
 Mixing is defined as a process “in which two or more ingredients in separate 
or roughly mixed condition are treated so that each particle of any one ingredients in 
as nearly as possible adjacent to a particle of each of the other ingredients.” 
Types of mixers
 
a)  Batch type 
Twin-shell, Double cone, Ribbon, Planetary, Fluidized air. 
b) Continuous 
Zigzag, Barrel, Blendex. 
 
 Granulation
10
  
 Granulation is a process making separate powder particle into a group by 
using granulating fluid. Granulating fluid may be water including or water heating, 
this depends on the nature of drug and other excipients used. The process of making 
of granules is termed as granulation and the technique and equipment used is 
granulation technology. 
 
Reasons for Granulation
11 
 To improve powder flow.  
 To improve compressibility.  
 To reduce fines.  
 To control the tendency of powders to segregate.  
 To control density.  
 To capture and fuse small quantities of active material 
 
Types of Granulation
12 
 Wet Granulation. 
 Dry Granulation. 
 Direct Compression. 
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Wet Granulation  
This is the most widely used method of tablet preparation. In this method the 
powders are bound by suitable binder by “adhesion”. The binder is added by diluting 
with suitable solvent prior to addition to the blended powders to form wet granules 
which in turn are dried suitably to expel the solvent to form dried granules. The 
surface tension forces and capillary pressure are primarily responsible for initial 
granules formation. The main advantage being it meets all the requirements for tablet 
formation though it is multistage, time consuming process. 
 
Dry Granulation  
  The dry granulation process is used to form granules without using a liquid 
solution. This type of process is recommended for products, which are sensitive to 
moisture and heat. Forming granules without moisture requires compacting and 
densifying the powders. Dry granulation can be done on a tablet press using slugging 
tooling. 
 
Direct Compression 
The tablets are made by directly compressing the powdered materials without 
modifying the physical nature of the materials itself. Direct compression is generally 
done for the crystalline materials having good physical properties such as flow 
property, compressibility etc. Main advantages of direct compression are time saving, 
safety of operations and low cost. 
. 
 Compression
7
 
 The ultimate test of a tablet formulation and granulation process is whether the 
granulation can be compressed on a high- speed tablet press. 
 During compression, the tablet press performs the following functions: 
 Filling of die cavity. 
 Precompression of granulation. 
 Compression of granulation. 
 Ejection of the tablet from the die cavity and take-off of compressed 
tablet. 
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1.1.1.6. PROBLEMS IN TABLETING
14
     
 Capping and Lamination  
 Picking and Sticking 
 Mottling 
 Double impression 
 
Capping and Lamination 
Capping is a term used to describe the partial or complete separation of the top 
or bottom crowns of a tablet from the main body of the tablet.  Lamination is the 
separation of a tablet into two or more distinct layers. 
 
Picking and Sticking 
Picking is a term used to describe the surface material from a tablet that is 
sticking to and being removed from the tablet’s surface by a punch. Sticking is the 
adhesion of granulation material to the die wall. 
 
Mottling 
Mottling is an unequal distribution of colour on a tablet, with light or dark 
areas standing out in another wise uniform surface. 
 
Double Impression 
This involves only punches that have monogram or other engraving on them. 
At the moment of compression the tablet receives the imprint of the punch. 
Sometimes it will receive double impression due to improper movement of lower 
punch. 
 
Preventive Methods: 
By proper mixing 
By improving the flow properties of granules 
By using proper camtracks which are responsible for punches movements. 
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1.1.1.7. EVALUATION OF TABLETS 
Tablets formulated may undergo physical and chemical changes thereby 
altering the bioavailability of the dosage form. These tablets are to be evaluated 
before dispensing to maintain their stability and bioavailability throughout its shelf 
life. Evaluation of tablets can be carried as follows: 
a) Unofficial tests 
 Tablet appearance 
 Organoleptic properties 
 Identification markings on tablet 
 Size and shape of the tablet 
 Thickness of tablet 
 Hardness of tablet 
 Friability of tablet 
 
b) Official tests 
 Weight variation test 
 Content uniformity test 
 Disintegration test 
 Dissolution test 
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1.2 ORALLY DISINTEGRATING TABLETS
 
 
1.2.1.
 
DEFINITION 
15, 16 
 Orally Disintegrating Tablets (ODT
S
) tablets are defined as uncoated or film 
coated tablets intended to be dispersed in water before administration giving a 
homogenous dispersion. Typically a tablet is dispersed in about 5-15 ml of water and 
the resulting dispersion is administered to the patients. Dispersible tablets are required 
to disintegrate within 3 minutes in water at 15-25
o
C. 
 
1.2.2. BACKGROUND OF THE INVENTION
16 
 Tablets and capsules are convenient pharmaceutical dosage forms for 
manufacturing, storage and ensure dosage uniformity. However, such dosage forms, 
like capsule and tablets, often present ingestion problems such as difficulty in 
swallowing, particularly for paediatric and geriatric populations. This may result in a 
high incidence of non- compliance and ineffective therapy, which may prove to be 
fatal in case of serious conditions. Suspension dosage forms could solve this problem, 
but they have other associated drawbacks like lower physical and chemical stability 
and high cost of manufacturing. Suspensions are also inconvenient to carry while 
travelling and also involve the risk of inaccurate measurement and dosing. Thus, there 
is need for oral pharmaceutical composition, which can be taken orally without need 
of swallowing it and act as a viable substitute for suspensions. Accordingly, provided 
are water dispersible tablet compositions, which can either be chewed or can be 
readily dispersed before oral administration. One of the key requirements of water 
dispersible tablet is that they should dissolve in an aqueous medium within a short 
time period of, for example, less than three minute, to form a smooth suspension 
without any coarse lumps. Dispersible tablets provide advantages of both tablets and 
liquid formulations. These are convenient to carry, easy to manufacture and more 
stable. 
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1.2.3. ODT
S 
TERMINOLOGY
17 
Orally disintegrating tablets are also known as mouth dissolving tablets, 
orodispersible tablets, fast disintegrating tablets, quick disintegrating tablets, fast 
dissolving tablets, rapid dissolving tablets, porous tablets, quick melt tablets or rapid 
melt tablets. 
 
1.2.4. ADVANTAGES OF ODT
S 18 
 Ease of administration to patients who refuse to swallow a tablet, such as 
pediatric, geriatric, mentally ill, disabled and uncooperative patients.  
 Rapid dissolution of drug and absorption may produce rapid onset of action. 
Pregastric absorption can result in improved bioavailability and as a result of 
reduced dosage, improved clinical performance by reducing side effects.  
 No need of water to swallow the dosage form, which is highly convenient 
feature for patients who are travelling and do not have immediate access to 
water.  
 Some drugs are absorbed from the mouth, pharynx and oesophagus as the 
saliva passes down into the stomach; in such cases bioavailability of these 
drugs increases.  
 Good mouth feel property of ODTS helps to change the psychology of 
medication as “bitter pill” particularly in pediatric patients.  
 Ability to provide advantages of liquid medication in the form of solid 
preparation.   
 
1.2.5. DISADVANTAGES OF ODT
S 
 Rapid disintegrating tablets are hygroscopic in nature so must be kept at 
controlled environment i.e. humidity and temperature.  
 For proper stability and safety, ODTS requires special packaging.  
 They usually have insufficient mechanical strength. Hence, careful handling is 
required.  
 Leave unpleasant taste and/or grittiness in mouth if not formulated properly. 
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1.2.6. CHALLENGES IN FORMULATING ODT
S 
Palatability
19 
As most drugs are unpalatable, orally disintegrating drug delivery systems 
usually contain the medicament in a taste-masked form. Delivery systems disintegrate 
or dissolve in patient’s oral cavity, thus releasing the active ingredients which come in 
contact with the taste buds; hence, taste-masking of the drugs becomes critical to 
patient compliance. 
Mechanical strength
20 
In order to allow ODT
S
 to disintegrate in the oral cavity, they are made of 
either very porous and soft-molded matrices or compressed into tablets with very low 
compression force, which makes the tablets friable and/or brittle, difficult to handle, 
and often requiring specialized peel-off blister packing that may add to the cost. Only 
few technologies can produce tablets that are sufficiently hard and durable to allow 
them to be packaged in multidose bottles, such as Wowtab® by Yamanouchi-Shaklee, 
and Durasolv® by CIMA labs. 
Hygroscopicity 
Several orally disintegrating dosage forms are hygroscopic and cannot maintain 
physical integrity under normal conditions of temperature and humidity. Hence, they 
need protection from humidity which calls for specialized product packaging. 
Amount of drug 
The application of technologies used for ODT
S
 is limited by the amount of drug 
that can be incorporated into each unit dose. For lyophilized dosage forms, the drug 
dose must be lower than 400 mg for insoluble drugs and less than 60 mg for soluble 
drugs. This parameter is particularly challenging when formulating a fast-dissolving 
oral films or wafers. 
Aqueous solubility 
Water-soluble drugs pose various formulation challenges because they form 
eutectic mixtures, which result in freezing-point depression and the formation of a 
glassy solid that may collapse upon drying because of loss of supporting structure 
during the sublimation process. Such collapse sometimes can be prevented by using 
various matrix-forming excipients such as mannitol than can induce crystallinity and 
hence, impart rigidity to the amorphous composite. 
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Size of tablet
21
 
The degree of ease when taking a tablet depends on its size. It has been 
reported that the easiest size of tablet to swallow is 7-8 mm while the easiest size to 
handle was one larger than 8 mm. Therefore, the tablet size that is both easy to take 
and easy to handle is difficult to achieve. 
Mouth feel
22 
The particles produced after disintegration of the ODT
S
 should be very small. 
ODT
S
 should not leave any residue in the mouth after oral administration. Addition of 
flavors and cooling agents like menthol enhance the mouth feel.   
Sensitivity to environmental conditions:  
ODT
S
 should have low sensitivity to environmental conditions such as 
humidity and temperature.   
Cost factor  
The technology adopted for an ODT
S
 should be acceptable in terms of cost of 
the final product. 
 
1.2.7. PATIENT FACTORS
23 
Orally disintegrating dosage forms are particularly suitable for patients, who 
for one reason or the other; find it inconvenient to swallow traditional tablets and 
capsules with water. These include the following: 
 Pediatric and geriatric patients who have difficulty in swallowing or chewing 
solid dosage forms. 
 Very elderly patients who may not be able to swallow a daily dose of 
antidepressant. 
 An eight-year old with allergies who desires a more convenient dosage form 
than antihistamine syrup. 
 A middle-aged woman undergoing radiation therapy for breast cancer may be 
too nauseous to swallow her H2-blocker. 
 A schizophrenic patient in an institutional setting who may try to hide a 
conventional tablet under his or her tongue to avoid their daily dose of an a 
typical antipsychotic. 
 A patient with persistent nausea, who may be in a journey or has little or no 
access to water. 
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1.2.8. EFFECTIVENESS FACTOR
24, 25 
Increased bioavailability and faster onset of action are a major claim of these 
formulations. Dispersion in saliva in oral cavity causes pregastric absorption from 
some formulations in those cases where drug dissolves quickly. Buccal, pharyngeal 
and gastric regions are all areas of absorption for many drugs
21.
 Any pregastric 
absorption avoids first pass metabolism and can be a great advantage in drugs that 
undergo a great deal of hepatic metabolism. Furthermore, safety profiles may be 
improved for drugs that produce significant amounts of toxic metabolites mediated by 
first-pass liver metabolism and gastric metabolism and for drugs that have a 
substantial fraction of absorption in the oral cavity and pregastric segments of GIT
22
. 
 
1.2.9. MANUFACTURING AND MARKETING FACTORS
26 
Developing new drug delivery technologies and utilizing them in product 
development is critical for pharmaceutical industries to survive, regardless of their 
size. As a drug nears the end of its patent life, it is common for pharmaceutical 
manufacturers to develop a given drug entity in a new and improved dosage form. A 
new dosage form allows a manufacturer to extend market exclusivity, unique product 
differentiation, value-added product line extension and extend patent protection, while 
offering its patient population a more convenient dosage form. This leads to increased 
revenue, while also targeting underserved and under-treated patient populations. 
Marketers build a better brand and company image when they offer a unique 
easier-to-take form that satisfies the need of an underserved patient population. 
 
1.2.10. IDEAL PROPERTIES
27 
An orally disintegrating tablet should 
 Require no water for oral administration, yet dissolve/disperse/disintegrate in 
mouth in a matter of seconds.  
 Have a pleasing mouth feel.    
 Have an acceptable taste masking property.  
 Be harder and less friable. 
 Leave minimal or no residue in mouth after administration. Exhibit low 
sensitivity to environmental conditions (temperature and humidity).  
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 Allow the manufacture of tablet using conventional processing and packaging 
equipment’s. Benefits of ODTS  was given below fig: 1 
 
 
Fig: 1 Benefits of Orally Disintegrating Tablets 
 
1.2.11. DISINTEGRANTS IN DISPERSIBLE TABLETS
28
 
  Disintegrants are agents added to tablet formulations to promote the break-up 
of the tablet into smaller fragments in an aqueous environment, thereby increasing the 
available surface area and promoting a more rapid release of the drug substance. In 
more recent years, several newer disintegrants have been developed, often called 
“super disintegrants”. These newer substance can be used at lower levels than 
conventionally used disintegrants. Three major mechanisms and factors affecting 
tablets disintegrants are suggested as swelling, porosity and capillary action and 
deformation. Three major group of compound that have been developed as 
superdisintegrants are modified starches, cross-linked polyvinylpyrrolidone and 
modified cellulose. 
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1.2.12. SUPERDISINTEGRANTS
29 
 In dispersible tablets, disintegrants plays a major role. Disintegrating agents 
are substances routinely included in the tablet formulations to aid in the breakup of 
the compacted mass when it is put into a fluid environment. They promote moisture 
penetration and dispersion of the tablet matrix. In recent years, several newer agents 
have been developed known as “Superdisintegrants”. These newer substance are more 
effective at lower concentrations with greater disintegrating efficiency and 
mechanical strength. On contact with water the superdisintegrants swell, hydrate, 
change volume or form and provide improved compressibility, compatibility and have 
no negative impact on the mechanical strength of formulations containing high-dose.  
 
1.2.12.1. SELECTION OF SUPERDISINTEGRANTS 
 Although superdisintegrants increase the rate of disintegration, but when used 
at high levels they can affect mouth feel, tablets hardness and friability. Hence, 
various ideal factors are to be considered while selecting an appropriate 
superdisintegrants for a particular formulation. A superdisintegrant should, 
 Produce rapid disintegration, when tablet comes in contact with saliva in the 
mouth/oral cavity. 
 Be compatible enough to produce less friable tablets. 
 Produce good mouth feel to the patients. Thus, small particle size is preferred 
to achieve patient compliance. 
 Have good flow, since it improves the flow characteristics of total blend. 
 
1.2.12.2. SUPERDISINTEGRANTS USED IN TABLETS
30 
 
Modified Starches 
Sodium starch glycolate is the sodium salt of a carboxymethyl ether of starch. 
It is effective at a concentration of 2-8%. It can take up more than 20 times its weight 
of water and the resulting high swelling capacity combined with rapid uptake of water 
accounts for its high disintegration rate and efficiency. It is available in various grades 
as Type A, B and C which differ in pH, viscosity and sodium content. Other special 
grades are available which are prepared with different solvents and thus the product 
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has a low moisture (<2%) and solvent content (<1%), thereby being useful for 
improving the stability of certain drugs. 
 
Modified Celluloses, Carboxymethylcellulose and its derivative 
 Cross-linked sodium carboxymethylcellulose is a white, free flowing powder 
with high absorption capacity. It has a high swelling capacity and thus provides rapid 
disintegration and drug dissolution at lower levels. It also has an outstanding water 
wicking capacity and its cross-linked chemical structure creates an insoluble 
hydrophilic, highly absorbent material resulting in excellent swelling properties. Its 
recommended concentration is 0.5-2.0%, which can be used up to 5.0%. L-HPC (Low 
substituted hydoxy propyl cellulose) is insoluble in water, swells rapidly and is used 
in the range of 1-5%. The grades LH- 11 and LH- 21 exhibit the greatest degree of 
swelling.  
 
Cross-linked Polyvinylpyrrolidone 
 It is a completely water insoluble polymer. It rapidly disperses and swells in 
water but does not gel even after prolonged exposure. The rate of swelling is highest 
among all the superdisintegrants and is effective at 1-3%. It acts by wicking, swelling 
and possibly some deformation recovery. The polymer has a small particle size 
distribution that imparts a smooth mouth feel and dissolves quickly. Varieties of 
grades are available commercially as per their particle size in order to achieve a 
uniform dispersion with the formulation. 
 
Soy Polysaccharide 
 It is a natural superdisintegrant that does not contain any starch or sugar, so 
can be used in nutritional products.  
 
Cross-linked Alginic acid 
 It is insoluble in water and disintegrates by swelling or wicking action. It is a 
hydrophilic colloidal substance, which has high sorption capacity. It is also available 
as salts of sodium and potassium.   
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Gellan gum 
 It is an anionic polysaccharide of linear tetrasaccharides, derived from 
Pseudomonas elodea having good superdisintegrant property similar to the modified 
starch and celluloses. 
 
Xanthan gum 
 Xanthan Gum derived from Xanthomonas campestris is official in USP with 
high hydrophilicity and low gelling tendency. It has low water solubility and 
extensive swelling properties for faster disintegration.   
 
Calcium silicate  
 It is a highly porous, light weight superdisintegrant, which acts by wicking 
action.  
 
 Ion exchange Resins 
  The INDION 414 has been used as a superdisintegrant for ODT
S
. It is 
chemically cross-linked polyacrylic, with a functional group of COO
– 
and the 
standard ionic form is K
+
. It has a high water uptake capacity. 
 
Other Superdisintegrants 
 Although there are many superdisintegrants, which show superior 
disintegration, the search for newer disintegrants is ongoing and researchers are 
experimenting with modified natural products like Formalin, Casein, Chitosan, 
Polymerized agar acryl amide, Xylan, Smecta, Key-jo-clay, Crosslinked 
carboxymethylguar and modified Topioca starch. 
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The different superdisintegrants used for the preparation of ODT
S 
are presented in 
Table 3. 
Table 3: Superdisintegrants used in the Preparation of ODT
S
 
31 
 
Name 
 
Composition 
 
Mechanism of action 
 
Special comment 
Croscarmellose 
(Ac-Di-Sol, 
Nymce ZSX, 
Primellose®, 
Solutab) 
Cross linked 
Cellulose 
Swells 4-8 folds in 
< 10 seconds. Both 
swelling and wicking.  
Swells in two 
dimensions. 
 
Crospovidone 
(Crospovidone 
M, Kollidon, 
Polyplasdone) 
Cross linked 
PVP 
Swells very little and 
returns to original size 
after compression but 
act by capillary action. 
Water insoluble and 
spongy in nature, 
produce porous 
tablet. 
Sodium starch 
glycolate 
(Explotab, 
Primogel) 
Cross linked 
Starch 
Swells 7-12 folds in 
< 30 seconds. 
Swells in three 
dimensions and high 
level serve as sustain 
release matrix. 
Alginic acid NF 
(Satialgine) 
Cross linked 
alginic acid 
Rapid swelling in 
Aqueous medium, 
wicking action. 
Promote 
disintegration in both 
dry or wet  
Granulation. 
Soy 
polysaccharides 
(Emcosoy) 
Natural 
superdisintegrant 
Swelling action Does not contain any 
starch or sugar. 
Used in nutritional 
products. 
Calcium silicate Silicate Wicking action Highly porous, 
Optimum 
concentration is 
between 20-40%. 
. 
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1.2.12.3. MECHANISM OF SUPERDISINTEGRANTS 
32, 33 
There are 4 major mechanisms for tablets disintegration and they are as 
follows: 
1. Swelling  
2. Porosity and Capillary action (Wicking)  
3. Disintegrating particle/particle repulsive forces  
4. Deformation 
 
SWELLING 
 The general mechanism of action for tablet disintegration, which is most 
widely accepted, is swelling. Tablets with high porosity due to lack of adequate 
swelling force show poor disintegration. Sufficient swelling force with low porosity is 
exerted in the tablet with low porosity. 
 
WICKING 
Effective disintegrants that do not swell are believed to impart their 
disintegrating action through porosity and capillary action. Tablet porosity provides 
pathways for the preparation of fluid into tablets. The disintegrant particles 
themselves act to enhance porosity and provide pathways into the tablet. Liquid is 
drawn up or “wicked” into these pathways through capillary action and rupture the 
interparticulate bonds causing the tablet to break apart. 
 
Fig: 2. Disintegration of Tablets by Wicking and Swelling Mechanism 
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PARTICLE- PARTICLE REPULSIVE FORCES 
Another mechanism of disintegrant attempts to explain the swelling of tablet 
made with ‘nonswellable’ disintegrants. Guyot-Hermann has proposed a particle 
repulsion theory based on the observation that nonswelling particle also cause 
disintegration of tablets. The electric repulsive forces between particles are the 
mechanism of disintegration and water is required for it. 
 
DEFORMATION 
Disintegrated particles get deformed; during compression of tablets and when 
these deformed particles come in contact with aqueous media or water they get into 
their normal structure. Swelling capacity of starch was improved during compression. 
The increase in size of the deformed particles produces breakup of tablets.  
The Mechanism of Deformation and Repulsion during the disintegration of 
tablets are shown in Fig: 3 
 
 
           
Fig: 3. Disintegration of Tablet by Deformation and Repulsion Mechanism 
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1.2.13. TECHNIQUES FOR FORMULATION OF ORALLY 
DISINTEGRATING TABLETS 
34
 
Many techniques have been reported for the formulation of orally 
disintegrating tablets. 
1. Freeze drying / Lyophilization 
2. Tablet Moulding 
3. Spray drying 
4. Sublimation 
5. Direct compression 
6. Mass extrusion 
 
FREEZE DRYING
 
Freeze drying is the process in which water is sublimed from the product after 
it is frozen. This technique creates an amorphous porous structure that can dissolve 
rapidly. A typical procedure involved in the manufacturing of ODT
S
 using this 
technique is mentioned here. The active drug is dissolved or dispersed in an aqueous 
solution of a carrier/polymer. The mixture is poured in the walls of the performed 
blister packs. The trays holding the blister packs are passed through liquid nitrogen 
freezing tunnel to freeze the drug solution or dispersion. Then the frozen blister packs 
are placed in refrigerated cabinets to continue the freeze-drying. After freeze-drying 
the aluminum foil backing is applied on a blister-sealing machine. Finally the blisters 
are packed and shipped. The freeze-drying technique has demonstrated improved 
absorption and increase in bioavailability. The major disadvantages of lyophillization 
technique are that it is expensive and time consuming; fragility makes conventional 
packaging unsuitable for these products and poor stability under stressed conditions. 
 
TABLET MOULDING 
Molding process is of two types (solvent method and heat method). Solvent 
method involves moistening the powder blend with a hydro alcoholic solvent 
followed by compression at low pressures in molded plates to form a wetted mass 
(compression molding). The solvent is then removed by air-drying. The tablets 
manufactured in this manner are less compact than compressed tablets and possess a 
porous structure that hastens dissolution. The heat molding process involves 
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preparation of a suspension that contains a drug, agar and sugar (e.g. mannitol or 
lactose) and pouring the suspension in the blister packaging wells, solidifying the agar 
at the room temperature to form a jelly and drying at 30
○
C under vacuum. The 
mechanical strength of molded tablets is a matter of great concern. Binders, which 
increase the mechanical strength of the tablets, needs to be incorporated. Taste 
masking is an added problem to this technology. The taste masked drug particles were 
prepared by spray congealing a molten mixture of hydrogenated cottonseed oil, 
sodium carbonate, lecithin, polyethylene glycol and an active ingredient into a lactose 
based tablet triturate form. Compared to the lyophillization technique, tablets 
produced by the molding technique are easier to scale up for industrial manufacture. 
 
SPRAY DRYING
35 
In this technique, gelatin can be used as a supporting agent and as a matrix, 
mannitol as a bulking agent and sodium starch glycolate or croscarmellose or 
crospovidone are used as superdisintegrants. Tablets manufactured from the spray-
dried powder have been reported to disintegrate in less than 20 seconds in aqueous 
medium. The formulation may contain bulking agent like mannitol and lactose, a 
superdisintegrant like sodium starch glycolate (or) croscarmellose sodium, acidic 
ingredient (citric acid) and alkaline ingredient (e.g. sodiumbicarbonate). This spray-
dried powder, when compressed into tablets may produce rapid disintegration and 
dissolution. 
 
SUBLIMATION 
In this method to generate a porous matrix, volatile ingredients are 
incorporated in the formulation that is later subjected to a process of sublimation. 
Highly volatile ingredients like ammonium bicarbonate, ammonium carbonate, 
benzoic acid, camphor, naphthalene, urea, urethane and phthalic anhydride may be 
compressed along with other excipients into a tablet. This volatile material is then 
removed by sublimation leaving behind a highly porous matrix. Tablets manufactured 
by this technique have reported to usually disintegrate in 10-20 sec.  
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DIRECT COMPRESSION
36 
Direct compression represents the simplest and most cost effective tablet 
manufacturing technique. This technique can be applied to preparation of ODT
S
 
because of the availability of improved excipients especially superdisintegrants and 
sugar based excipients. 
 
(a)Super Disintegrants: 
In many orally disintegrating tablets technologies based on direct 
compression, the addition of superdisintegrants increase the rate of disintegration and 
hence the dissolution. The presence of other formulation ingredients such as water-
soluble excipients and effervescent agents further hastens the process of 
disintegration. 
 
(b)Sugar Based Excipients: 
 This is another approach to manufacture ODT
S
 by direct compression method. 
The use of sugar based excipients especially bulking agents like dextrose, fructose, 
isomalt, lactilol, maltilol, maltose, mannitol, sorbitol, starch hydrolysate, polydextrose 
and xylitol will display high aqueous solubility and sweetness and hence impart taste 
masking property and a pleasing mouth feel. Mizumito et al have classified sugar-
based excipients into 2 types on the basis of molding and dissolution rate. 
Type 1 Saccharides (lactose and mannitol) exhibit low mould ability but high 
dissolution rate. 
Type 2 Saccharides (maltose and maltilol) exhibit high mould ability and low 
dissolution rate. 
 
MASS EXTRUSION
37 
This technology involves softening the active blend using the solvent mixture 
of water-soluble polyethylene glycol and methanol and subsequent expulsion of 
softened mass through the extruder or syringe to get a cylinder of the product into 
even segments and using heated blade to form tablet. The dried cylinder can also be 
used to coat granules for bitter drugs and thereby achieve taste masking. 
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1.2.14. PATENT TECHNOLOGIES FOR ORALLY DISINTEGRATING 
TABLETS
38 
 
1. Zydis Technology   
2. Durasolv Technology  
3. Orasolv Technology  
4. Wow tab Technology  
5. Flash Dose Technology  
6. FlashTab Technology  
7. Oraquick Technology  
8. Nanocrystal Technology 
 
Zydis Technology   
It was patented by Zydis. In this technology, the drug is entrapped within the 
matrix of fast dissolving carrier. The product is a unique freeze dried tablet that 
dissolves on tongue within 2-3 sec. 
Durasolv Technology  
It was patented by CIMA Labs. In this technology, drug is mixed with fillers 
and lubricant and tablets ware prepared using conventional tableting machines. 
Orasolv Technology  
It was also patented by CIMA Labs. This technology produces tablets 
comprising of taste masked medicaments and effervescent disintegrating agents 
prepared by direct compression method. 
Wow Tab Technology
39 
It was patented by Yamanouchi Pharmaceutical Co. WOW refers to With out 
Water. This technology utilizes combinations of low and high mouldability 
saccharides to obtain rapidly melting tablets. 
Flash Dose Technology  
It was patented by Fuisz. This technology produces tablets consisting of self-
binding shear form matrix called as “floss” prepared by flash heating process. 
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FlashTab Technology  
It was patented by Prographarm laboratories. In this technology, active 
ingredients are made into microgranules using techniques like coacervation or 
microencapsulation and tableted using conventional technology. 
Oraquick Technology  
It was patented by KV Pharmaceuticals. In this technology, drug is 
microencapsulated and surrounded by a matrix making it more pliable. 
Nanocrystal Technology 
Rate of dissolution can be increased by decreasing the particle size. In this 
technology, drugs are milled to small particles <1000 nm which is then combined 
with water soluble ingredients, lyophilized and finally blister packed. 
 
1.2.15. STAGES OF DISINTEGRATION 
 The different stages of disintegration of ODT
S
 were shown in Fig: 4 
 
Fig: 4 Disintegration Stages of Dispersible Tablets 
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1.2.16. EVALUATION OF ORALLY DISINTEGRATING TABLETS
 40 
Hardness 
A significant strength of ODT
S
 is difficult to achieve due to the specialized 
processes and ingredients used in the manufacturing. The limit of hardness for the 
ODT
S
 is usually kept in a lower range to facilitate early disintegration in the mouth. 
The hardness of the tablet may be measured using conventional hardness test. 
 
Friability 
To achieve % friability within the limit for an ODT
S
 is a challenge for a 
formulator since all the methods of manufacturing ODT
S
 are responsible for increase 
in the % friability values. Thus, it is necessary that this parameter should be evaluated 
and the results should be within bound limits (0.1-0.9%). 
 
Wetting time and Water absorption ratio 
Wetting time of dosage form is related with the contact angle. Wetting time of 
the ODT
S
 is another important parameter, which needs to be assessed to give an 
insight into the disintegration properties of the tablet. Lower wetting time implies a 
quicker disintegration of the tablet. The wetting time of the tablets can be measured 
by using the simple procedure. Five circular tissue papers of 10cm diameter are 
placed in a petri dish. Ten milliliters of water soluble dye solution is added to petri 
dish. A tablet is carefully placed on the surface of the tissue paper. The time required 
for water to reach upper surface of the tablet is noted as the wetting time. For 
measuring water absorption ratio the weight of the tablet before keeping in the petri 
dish is noted (Wb). The wetted tablet from the petri dish is taken and reweighed (Wa). 
The water absorption ratio, R can be the determined according to the following 
equation. 
                                          R = 100 (Wa-Wb) / Wb 
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Moisture uptake studies 
Moisture uptake studies for ODT
S
 should be conducted to assess the stability 
of the formulation. Ten tablets from each formulation were kept in a desiccator over 
calcium chloride at 37
0
 C for 24h. The tablets were then weighed and exposed to 75% 
relative humidity, at room temperature for 2 weeks. Required humidity was achieved 
by keeping saturated sodium chloride solution at the bottom of the desiccator for 3 
days. One tablet as control (without superdisintegrant) was kept to assess the moisture 
uptake due to other excipients. Tablets were weighed and the percentage increase in 
weight was recorded. 
 
Disintegration test 
The time for disintegration of ODT
S
 is generally<1min and the actual 
disintegration time that patients can experience ranges from 5 to 30s. The standard 
procedure of performing disintegration test for these dosage forms has several 
limitations and they do not suffice the measurement of very short disintegration times. 
The disintegration test for ODT
S
 should mimic disintegration in mouth with in 
salivary contents. 
 
Dissolution test 
Dissolution media such as 0.1 N HCl, pH 4.5 and pH 6.8 buffers should be 
used for evaluation of ODT
S
 in the same way as their ordinary tablet counter parts. 
USP dissolution apparatus 2 (paddle) is most suitable and common choice for 
dissolution test of ODT
S
 tablets, where a paddle speed of 50 rpm is commonly used. 
Typically the dissolution of ODT
S
 is very fast when using USP monograph 
conditions. Hence slower paddle speeds may be utilized to obtain a comparative 
profile. The USP dissolution apparatus 1 (basket) may have certain applications for 
ODT
S
 but is used less frequently due to specific physical properties of tablets. 
Specifically tablet fragments or disintegration tablet masses may become trapped on 
the inside top of the basket at the spindle where little or no effective stirring occurs, 
yielding irreproducible results in dissolution profile. 
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CHAPTER - 2 
 
REVIEW OF LITERATURE 
 
Avani R. Gosai et al., (2008)
41
 formulated and evaluated oro dispersible tablets of 
Ondansteron hydrochloride by direct compression method. The tablets were prepared 
by using sodium starch glycolate and croscarmellose sodium as superdisintegrants. 
Microcrystalline cellulose was used as diluent. Mannitol, mint flavor, sodium 
saccharin were used to enhance the organoleptic properties of tablets. The tablets 
were evaluated for post compression parameters such as weight variation, friability 
hardness, in vitro disintegration time, in vivo disintegration time, wetting time and 
drug release characteristics. All the parameters were found within the U.S.P limits. 
Hardness and friability data indicated good mechanical strength of tablets. The results 
showed in vitro disintegration time and in vivo disintegration time of the tablets was 
within 3 to 5 seconds. Dissolution study revealed faster drug release rate of 
Ondansetron hydrochloride from the tablets as compared with marketed conventional 
tablet of Ondansetron hydrochloride. The study concluded that batch S2C2 showed 
98.63% drug release at the end of 30 minutes and emerged as best formulation. 
 
Mohammad Ali Shahtalebi et al.,
 
(2015)
42 
formulated and evaluated an orally 
disintegrating tablet containing Ondansetron by using semisynthetic and natural 
superdisintegrants. Orodispersible tablets were prepared by direct compression using 
natural superdisintegrant (Karaya gum) and semi-synthetic superdisintegrant 
(croscarmellose). The prepared tablets were evaluated for hardness, friability, 
thickness, drug content uniformity, wetting time and water absorption ratio. 
According to the results of optimized batches, the best concentrations of 
superdisintegrants (7.88 mg karaya gum and 7.78 mg croscarmellose) gave rapid 
disintegration in 31 seconds and showed 99% drug release within 5 minutes. The 
study concludes that karaya gum, a natural superdisintegrant, gives rapid 
disintegration and high release when used with synthetic superdisintegrant in the 
formulation of ODT
S
. 
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Sheshala R et al.,
 
(2011)
43
 formulated taste-masked orally disintegrating tablets of 
Ondansetron, a bitter drug using different superdisintegrants by wet granulation 
technique. Microcrystalline cellulose (Avicel) as diluent and disintegrant in addition 
to aspartame as a sweetener were used in all formulations. The prepared tablets were 
evaluated for weight variation, thickness, hardness, friability, drug content, water 
content, in vitro disintegration time and in vitro drug release. The tablets hardness 
were maintained in the range of 2-3 kg and friability was <1% for all batches. All 
formulations disintegrated rapidly in vitro within 5.83 to 33.0 seconds. The optimized 
formulation containing 15% Polyplasdone XL-10 released more than 90% of drug 
within 5 minutes and the release was comparable to that of a commercial product. In 
human volunteers, optimized formulation was found to have a pleasant taste and 
mouth feel and they disintegrated in the oral cavity within 12 seconds. The stability 
results were also found to be satisfactory. A pharmacokinetic study with the 
optimized formulation was performed in comparison with a reference (Zofer MD 8®) 
and they were found to be bioequivalent. In conclusion, a cost effective Ondansetron 
orally disintegrating tablet was successfully prepared with acceptable hardness, 
desirable taste and rapid disintegration in the oral cavity. 
 
Nitin Bansal et al., (2011)
44
 developed orally disintegrating tablets of Ondansetron 
HCl by dry granulation method using different concentrations of superdisintegrants 
such as modified gum karaya, modified natural agar, croscarmellose sodium and 
sodium starch glycollate. The formulations were evaluated for weight variation, 
hardness, friability, drug content, wetting time, in vitro disintegration time and in vitro 
dissolution study. The results showed that modified gum karaya and modified natural 
agar produce rapid disintegration of tablets. The optimized formulation showed 
acceptable physical characteristics and produced complete drug release within 6 
minutes. The incorporation of clove oil provided additional properties such as 
symptomatic relief from nausea and vomiting, good mouth feel and taste masking. 
Kinetic analysis showed that drug release from optimized formulation was adequately 
described by first order release kinetics. The results revealed that modified gum 
karaya and modified natural agar can be used as an alternative superdisintegrants to 
commonly available synthetic and semisynthetic superdisintegrants due to their low 
cost, biocompatibility as well as easily availability. 
Chapter-2                                                                  Review of Literature 
 
S.B.C.P                                Department of Pharmaceutics                           Page 33 
 
Suresh et al.,
 
(2007)
45 
prepared and evaluated Salbutamol sulphate ODT
S
 for asthma 
by wet granulation method using sublimable components viz camphor and ammonium 
bicarbonate. The prepared tablets were evaluated for weight variation, hardness, 
friability, drug content and disintegration time. All the prepared tablets disintegrated 
in less than a minute. The formulations tested for all the evaluation parameters were 
found to be within the I.P limits. Formulation F3 showed minimum disintegration 
time of 5 seconds and emerged as best formulation. 
 
Kitawat S et al., (2013)
46  
reviewed an increasing demand for more patient compliant 
dosage form and a novel method is the development of orally disintegrating tablets 
which dissolve or disintegrates instantly on the patient tongue or buccal mucosa. It is 
suited for tablets undergoing high first pass metabolism and is used for improving 
bioavailability with reducing dosing frequency to minimize side effect and make it 
more cost effective. Oral route having the highest patient compliance is regarded as 
the most convenient, safest and also the most economical method of drug delivery.  
 
Radke R.S et al.,
 
(2009)
47
 prepared orodispersible tablets of Baclofen  using various 
concentrations of superdisintegrants like Ac-Di-Sol, crospovidone, sodium starch 
glycolate by direct compression method. Nine formulations having superdisintegrants 
at different concentration levels were prepared. These tablets were evaluated for drug 
content, weight variation, friability, hardness, wetting time and disintegration time. 
Among all the formulations, F3 containing Ac-Di-Sol showed superior organoleptic 
properties along with excellent disintegration time and drug release. The percentage 
drug release of batch F3 showed 100.51% at the end of 16 minutes and emerged as 
best formulation. Hence it was concluded that superdisintegrants addition technique is 
useful for preparing orodispersible tablets by direct compression method. 
 
G.Rajalakshmi et al.,
 
(2010)
48
 formulated Pheniramine maleate orodispersible 
tablets, a selective H1 receptor antagonist by direct compression method using 
superdisintegrants like croscarmellose sodium, crospovidone, sodium starch 
glycollate, low hydroxy propyl cellulose and pre gelatinized starch in different ratios. 
The blend was examined for various pre compression parameters. Tablets were 
evaluated by measuring hardness, friability, content uniformity, weight variation and 
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drug release pattern. All the tablets met the pharmacopoeial requirements for physical 
tests. The formulation with increase in concentration of superdisintegrants, showed 
rapid drug release. Stability studies were also perfomed.  Dissolution studies indicated 
that the tablets containing crospovidone and croscarmellose sodium showed rapid 
dissolution compared to other disintegrants releasing almost 100% of the drug in six 
minutes. 
 
Metker Vishal et al., (2011)
49
 developed mouth dissolving tablets of Lornoxicam 
using KYRON T-314 (Polacrillin Potassium) as a novel superdisintegrant. Mouth 
dissolving tablets of Lornoxicam were prepared by wet granulation technique using 
KYRON T-314 as superdisintegrant and menthol as subliming agent. The prepared 
tablets were evaluated for thickness, hardness, friability, weight variation, wetting 
time, in vitro dispersion time, drug content and in vitro dissolution study. All the 
evaluation parameters were found to be within the U.S.P limits. The formulation F5 
prepared by direct sublimation of menthol showed 78.37% drug release at the end of 5 
minutes when compared to other formulations. The formulation F5 was concluded as 
the best formulation. The present study demonstrated potentials for rapid absorption, 
improved bioavailability, effective therapy and patient compliance.  
 
Shailaja T et al., (2012)
50
 formulated and evaluated orodispersible tablets of 
Metoprolol tartrate with natural and synthetic superdisintegrants. The tablets were 
prepared by direct compression method using different ratio of natural 
superdisintegrant (agar, treated agar) and synthetic superdisintegrants (sodium starch 
glycolate, croscarmellose sodium and crospovidone) at concentrations ranging from 
3%-12%. The blend of all formulations were evaluated for various precompression 
parameters such as angle of repose, bulk density, tapped density, compressibility 
index and Hausner’s ratio. The prepared tablets were evaluated for various parameters 
like weight variation, thickness, hardness, friability, wetting time, water absorption 
ratio, disintegration time, content uniformity and in vitro drug release. The 
formulation treated with agar have shown promising results compared to other 
formulation with semisynthetic superdisintegrants. The optimized formulation was 
subjected to stability studies for three months as per ICH guidelines. Disintegration 
times of formulations treated with agar were found to be in the range 3-19 seconds 
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and 95-100% drug release was observed in 5 minutes. The optimized formulation was 
found to be stable with insignificant change in the hardness, disintegration time, drug 
content and in vitro drug release.  
 
Prasanth V V et al., (2013)
51
 developed oro dispersible tablets of Salbutamol 
sulphate using croscarmellose sodium, sodium starch glycolate, alginic acid, modified 
agar and modified guar gum as superdisintegrants. Precompression parameters were 
carried out to study the flow properties of powder to achieve uniformity of tablet 
weight and the values were found within the permissible limits. The tablets were 
prepared by direct compression method and possess a weight variation below ± 7.5%, 
hardness of 3.09 to 3.55 Kg/cm
2
, percentage friability of 0.310 to 0.698, in vitro 
dispersion time of 22 to 54 seconds. The drug content uniformity was in between 
95.94 to 99.67%, water absorption ratio 58.58 to 87.06%, wetting time 18 to 49.66 
seconds and the in vitro drug release study showed more than 85% of the drug was 
released from all formulations within 15 minutes. Among all, formulation F12 was 
considered to be the best formulation which showed drug release upto 98.90% within 
15 minutes and indicated rapid absorption, effective therapy and improved 
bioavailability. 
 
Akula Nikhil Prashant et al., (2015)
52
 formulated oral disintegrating tablets of 
Nateglinide by direct compression method by the addition of superdisintegrants. Nine 
batches (F1-F9) of oral disintegrating tablets of Nateglinide were prepared by using 
superdisintegrants like crospovidone, croscromellose sodium and sodium starch 
glycolate in variable concentrations along with other excipents for the development of 
optimized formulation. All the formulations were subjected to evaluation studies like 
weight variation, hardness, friability, drug content, in vitro disintegration and in vitro 
dissolution studies and the results were found to be within the U.S.P limits. The 
formulation F8 was identified as best amongst all the other formulations and its 
release was found to be 91.78% within 35 minutes and it showed a constant release up 
to 45 minutes. The best formulation (F8) showed linearity when compared with 
marketed product. On the basis of the results, the formulation F8 containing 
crospovidone was considered as ideal among all other formulations used for the 
development of Nateglinide tablets. 
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T. Balakrishna et al., (2016)
53 formulated Zolmitriptan orodispersible tablets using 
superdisintegrants such as croscarmellose sodium and crospovidone. The tablets were 
prepared by direct compression method. The compressed tablets were evaluated for 
postcompression parameters such as weight uniformity, hardness, friability, drug 
content and in vitro dissolution study. All the evaluation parameters were found to be 
within the U.S.P limits. Rapid release of Zolmitriptan from orodispersible tablets was 
observed which was influenced by the concentration of superdisintegrants. Among the 
various tablet formulations, F6 showed rapid drug release (99.8%) when compared to 
marketed formulation (84.89%) and emerged as best formulation. 
 
G. Sandhyarani et al., (2016)
 54
 formulated and evaluated orodispersible tablets of 
Domperidone by direct compression method. Seven formulations were prepared with 
different concentrations of superdisintegrants such as sodium starch glycolate, 
croscarmellose sodium and crospovidone. The prepared granules were evaluated for 
precompression parameters such as angle of repose, bulk density, compressibility 
index and Hausner’s ratio. The formulated tablets were evaluated for thickness, 
hardness, weight variation, friability, drug content, water absorption ratio, wetting 
time, in vitro disintegration time and in vitro dissolution time. All the parameters were 
found to be within the acceptable limits. Formulation F5 (croscarmellose sodium + 
crospovidone)  showed better water absorption ratio 76.73±2.88%, wetting time 
26.66±2.08 seconds, disintegration time 25±1.0 seconds compared with other 
formulations and considered  as better formulation.  
 
A. Bharathi et al., (2012)
55
 formulated orally  disintegrating  tablets of Amlodipine 
Besylate by direct  compression method using  superdisintegrants  like crospovidone, 
croscarmellose  sodium  and  sodium  starch  glycolate.. All the formulations were 
evaluated for pre compression, post compression parameters and the results were 
found to be within the U.S.P limits. Wetting time of formulations containing 
croscarmellose sodium was least and showed fast disintegration. Among the nine 
formulations studied, F9 showed short dispersion time with maximum drug realease 
(99.59%) in 20 minutes. The study concluded that combinations of superdisintegrants 
were found to be better in the formulation of fast dissolving tablets of Amlodipine 
Besylate rather than using alone.  
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S. Ramu et al., (2014)
 56 
formulated and evaluated Valsartan mouth dissolving tablets 
by direct compression method. Total nine formulations were prepared by using 
various concentrations of superdisintegrants such as sodium starch glycolate, avicel 
pH102 and low HPC. The prepared tablets were evaluated for post compression 
parameters such as weight variation, hardness, friability, wetting time, in vitro 
dispersion time, drug content and in vitro dissolution studies. Formulations F1, F2, 
F3, released 89.83%, 91.10%, 96.20%, of drug respectively, Formulation F4, F5, and 
F6, released 85.11%, 88.71% and 90.44% respectively and formulation F7, F8, F9, 
released 78.26%, 82.26%, 85.31%, of drug respectively, at end of 15 minutes. 
Amongst all the formulations, Valsartan mouth dissolving tablets formulated by using 
sodium starch glycolate as superdisintegrant, showed good in vitro disintegration time 
(8.00 ± 1.023 sec), in vitro dispersion time (14.33 ± 1.24 sec), compared to other 
superdisintegrants. The optimized formulation (F3) containing sodium starch 
glycolate, as superdisintegrant showed best results compared to other formulations 
and emerged as the best formulation. 
 
L. Divya et al., (2014)
57
 formulated Fluoxeitine hydrochloride oral dispersible tablets 
by three methods viz direct compression, wet granulation and sublimation method 
using superdisintegrants such as croscarmellose sodium and crospovidone. The 
prepared granules were evaluated for precompression parameters such as bulk 
density, tapped density, Hausner’s ratio, compressibility index and angle of repose. 
The prepared tablets were evaluated for post compression parameters like hardness, 
friability, drug content, weight variation, disintegration time, wetting time, water 
absorption ratio, in vitro dispersion time and in vitro dissolution study. All the 
parameters were found to be with in the U.S.P limits. From the data obtained, it was 
observed that formulations with crospovidone as disintegrant exhibit quicker 
dispersion and wetting time compared to croscarmellose sodium. The percentage drug 
release was shown more in case of croscarmellose sodium than crospovidone. The 
formulation F6 containing combination of two superdisintegrants showed more 
percentage drug release (98%) at the end of 15 minutes than other formulations and 
emerged as best formulation. 
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Jain et al., (2012)
58
 formulated Oxcarbazepine oral disintegrating tablets by direct 
compression method using various ingredients like crospovidone, mannitol, sodium 
lauryl sulphate (SLS), magnesium stearate in different concentrations (5-10% 50%, 2-
6%, 1 %). Chemical incompatibility studies confirmed that there was no interaction 
between drug and excipients used in the formulations. The tablets were evaluated for 
hardness, friability, weight variation, wetting time, water absorption ratio, assay and 
in vitro dissolution study. All the tablets were found to be within the U.S.P limits. The 
formulation F8 showed drug release of 98.05% at the end of 15 minutes and emerged 
as the best formulation. 
P.Rohini et al., (2014)
59 
formulated orally disintegrating tablets of Rosuvastatin by 
direct compression technique. Fourteen batches were prepared using various 
superdisintegrants like sodium starch glycolate, croscarmellose sodium, Lycoat-
RS720 and crospovidone in different concentrations. All the formulations were 
evaluated for weight variation, hardness, friability, in vitro disintegration time, drug 
content, wetting time and in vitro dissolution study. The results of all the tablets were 
found to be within the I.P limits. Among all the formulations, F13 (containing 8% of 
super disintegrants i.e. crospovidone and sodium starch glycolate (1:1) was 
considered to be the best formulation, which released upto 97% drug in 5 minutes. A 
comparative study of in vitro drug release was made with marketed product of 
Rosuvastatin which showed 93% drug release in one hour. The study concluded that 
the formulated tablets of Rosuvastatin containing crospovidone and sodium starch 
glycolate are better and effective than conventional tablets to meet patient 
compliance. 
Bhupendra G et al., (2010)
60
 formulated orally disintegrating tablet of Cinnarizine 
by direct compression method. The superdisintegrants such as crospovidone, 
croscarmellose sodium and sodium starch glycolate were used. The prepared tablets 
were evaluated for weight variation, thickness, hardness, friability, taste, drug content, 
in vitro disintegrating time and in vitro drug release. Other parameters such as wetting 
time, water absorption ratio and drug-excipient compatibility were also evaluated. All 
the parameters were found to be within the I.P limits. Effect of varying concentrations 
of different superdisintegrants on disintegration time was studied. The formulation 
CP5 containing 6% crospovidone showed better drug release (95%) at the end of 15 
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minutes and disintegrating time (25 seconds). The drug release of formulation CP5 
containing 6% crospovidone (CP5) when compared to the marketed conventional 
Cinnarizine tablet showed faster drug release and emerged as best formulation. 
 
Kok khiang peh et al., (2013)
61
 briefed the emergence of orally disintegrating dosage 
forms as a breakthrough solution for non-compliance. Orally disintegrating dosage 
forms come in 2 types, namely orally disintegrating tablet (ODT) and orally 
disintegrating film (ODF). This article discussed the non-compliances issue in 
general, development of orally disintegrating dosage forms (ODT and ODF), their 
characteristics, advantages, formulation challenges, manufacturing methods, examples 
of patented technology of ODT, examples of ODF product, taste masking 
technologies, patients’ acceptance and preference and lastly counseling.  
 
Patel Kirtan kumar et al., (2012)
62 
formulated oro-dispersible tablets of Montelukast 
sodium using combination of the superdisintegrants and ludiflash by direct 
compression method. Three formulations having combination of superdisintegrants 
and three formulations having ludiflash at different concentration levels were 
prepared. The prepared tablets were evaluated for the post compression parameters 
such as hardness, friability, weight variation, wetting time, drug content, in vitro 
disintegration and in vitro dissolution study. All the parameters were found to be 
within the U.S.P limits. A rapid disintegration was observed for the formulation F6 
containing 66.7% ludiflash. The in vitro dissolution profile  indicated that among all 
the formulations, faster and maximum drug release was obtained from formulation F6 
containing ludiflash and emerged as best formulation. 
 
YashPaul et al., (2011)
63 
formulated taste masked dispersible tablets of Zidovudine 
by direct compression method using croscarmellose sodium (Ac-di-sol) as 
disintegrant. Surelease clear (E-7-19010) in concentration range of 0.044mL/tab to 
0.052mL/tab completely masked the taste of Zidovudine. The prepared tablets were 
evaluated for general appearance, drug content, weight variation, thickness, hardness, 
friability, taste evaluation, mouth feel, in vitro dispersion time and in vitro dissolution 
studies.  The results showed that all the parameters were found within the limits. 
Results also revealed that the tablets containing taste enhancers and surelease had a 
Chapter-2                                                                  Review of Literature 
 
S.B.C.P                                Department of Pharmaceutics                           Page 40 
 
good palatability. Oral dispersible tablets prepared using Surelease 0.044mL/tablet 
and Ac-di-sol 6% possessed least disintegration time (18.9 seconds), pleasant taste 
and offered better dissolution profile (98%) than all other dispersible tablet 
formulations and marketed conventional tablet formulation of Zidovudine. 
 
Milind P Wagh et al., (2010)
64
 developed fast dissolving tablets of Aceclofenac by 
direct compression method after incorporating superdisintegrants croscarmellose 
sodium, crospovidone and sodium starch glycolate. Nine formulations having 
superdisintegrants at different concentration (10, 15, 20 mg) level were prepared and 
the effect of superdisintegrants on wetting time, dispersion time, drug content and in 
vitro release has been studied. Tablets containing croscarmellose sodium showed 
excellent in vitro dispersion time (23 minutes) and in vitro drug release (99.21% at the 
end of 30 minutes) as compared to other formulations. The results revealed that 
formulation F3 showed short dispersion time with maximum drug release in 30 
minutes and emerged as best formulation. 
 
Yogananda. R et al., (2009)
65
 formulated Piroxicam dispersible tablets by wet 
granulation and direct compression method using various natural disintegrating agents 
such as ispaghula husk, cassia tora and crosslinked tragacanth. The prepared tablets 
were evaluated for the post compression parameters such as hardness, friability, 
weight variation, wetting time, drug content, in vitro disintegration and in vitro 
dissolution study. All the parameters were found to be within the I.P limits. The study 
reveals that the formulation prepared by direct compression (F5) exhibits better 
dissolution rate (86%) at the end of 15 minutes and disintegration time (60 seconds) at 
low concentration of natural disintegrants. Hence the formulation F5 was selected as 
the best formulation. 
 
S.B. Jadhav et al., (2011)
66
 formulated dispersible tablets of Diltiazem HCl using wet 
granulation method for enhanced patient compliance. Dispersible tablets were 
prepared using superdisintegrants such as croscarmellose sodium (Ac-Di-Sol) and 
sodium starch glycolate. All the formulations were evaluated for the post compression 
parameters of dispersible tablets. It was observed that all the formulations were 
acceptable with reasonable limits of standard required for dispersible tablets. Among 
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the formulations, batch A1 containing Ac-Di-Sol showed excellent in vitro 
disintegration time (35 seconds) and in vitro drug release (100%) as compared to 
other formulations and selected as best formulation. The study concluded that 
dispersible tablets with enhanced dissolution rate can be made using selected 
superdisintegrants. 
 
Radha Rani Earl et al.,(2016)
67
 prepared fast dissolving tablets of Diclofenac 
sodium using 3 different superdisintegrants like sodium starch glycolate, 
croscarmellose sodium and crospovidone by direct compression technique. The 
precompression parameters of the prepared tablet blend like angle of repose, bulk 
density, tapped density, carr’s index, Hausner’s ratio and the post compression 
parameters like hardness, friability, weight variation, in vitro dispersion time, wetting 
time, water absorption ratio, in vitro disintegration time and in vitro drug dissolution 
were evaluated. All the parameters were found to be within the I.P limits. It was 
concluded that formulation F10 containing crospovidone showed better release 97.7% 
at the end of 20 minutes and emerged as best formulation.   
 
K. Gnanaprakash et al., (2009)
68
 developed fast dissolving tablets of Valdecoxib by 
direct compression method. The fast dissolving tablets of Valdecoxib was prepared 
with some carriers (polymers) and superdisintegrants such as polyvinyl pyrrolidone 
(PVP), sodiumcarboxy methyl cellulose (SCMC), crospovidone NF and β – 
Cyclodextrin. The above mentioned carriers and superdisintegrants were taken in 
different proportions of 5, 10 and 15%. The blend was examined for Angle of repose, 
bulk density, compressibility index and Hausner’s ratio. The prepared tablets were 
evaluated for hardness, drug content uniformity, friability, in vitro disintegration time 
and in vitro dissolution rate.  All the parameters were found to be within the I.P limits. 
The formulation F9 containing crospovidone showed maximum drug release of 
99.88% at the end of 10 minutes and emerged as the best formulation and the drug 
release was found to be comparable with the marketed dispersible tablet of 
Valdecoxib. 
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  Snehal T Hase et al., (2015)
69
 developed mouth dissolving tablets of Pioglitazone 
HCl using superdisintegrants such as sodium starch glycolate and crospovidone by 
direct compression technique. The tablets were evaluated for weight variation, 
hardness, percentage friability, wetting time and disintegration time. Eight 
formulations having superdisintegrants in different concentration levels were prepared 
to access their efficiency and critical concentration level. Tablets containing sodium 
starch glycolate along with crospovidone (F5) showed excellent disintegration time 
(52 seconds) and in vitro drug release 98.9% at the end of 25 minutes compared to 
other formulations and was selected as better formulation. 
 
Bhaskar Umarji et al., (2012)
70
  formulated fast dissolving tablets of Levocetrizine 
HCl using sodium starch glycolate, croscarmellose sodium and crospovidone as 
superdisintegrants by direct compression method. The tablets prepared were 
evaluated for various parameters like weight variation, hardness, friability, in vitro 
dispersion time, drug content, wetting time, in vitro drug release, FT-IR and XRD 
studies. The tablets prepared by direct compression method possess weight variation 
below ±7.5%, hardness of 3 to 4.0 Kg/cm², percentage friability of 0.51 to 0.85 %,  
in vitro dispersion time of 17 to 58 seconds, wetting time of 13 to 48 seconds and    
in vitro drug release of 94 % to 99 % within 20 minutes. The formulation (MD6) 
containing crospovidone and sodium starch glycolate showed better disintegration 
time and 99% drug release within 20 minutes and emerged as best formulation. 
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CHAPTER – 3 
 
AIM AND PLAN OF WORK 
 
3.1 AIM AND OBJECTIVE OF WORK 
 
 The aim of the present study is to design and evaluate the orally disintegrating 
tablets of Ondansetron hydrochloride using various superdisintegrants and 
compare with marketed Ondansetron hydrochloride dispersible tablets. 
 
 The main problem encountered with common oral dosage forms is that they 
have to be swallowed along with water and during the travel or if drinking 
water is not available or for dysphagic patients, it is difficult to administer 
these drugs and hence it is beneficial to administer such drugs as orally 
disintegrating tablets. Moreover patients finding difficult to swallow these 
tablets, especially elders and pediatrics do not comply with prescription, 
which results in patient noncompliance. 
 
 Thus ODTS are beneficial to patients who find it difficult to swallow tablets 
and moreover some of the drugs which are soluble in saliva are absorbed from 
the mouth, pharynx and oesophagus thereby avoiding first pass metabolism 
which enhances bioavailability of the drug. 
 
The objective of the work is to prevent inherent drawbacks associated with 
conventional tablets such as risk of choking, bitter taste and difficult in swallowing by 
formulating orally disintegrating tablets of Ondansetron HCl there by providing faster 
disintegration and rapid release, bypassing first pass effect, improved patient 
compliance and therapeutic effectiveness. 
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3.2 PLAN OF WORK 
 
The present work was carried out to formulate orally disintegrating tablets of 
Ondansetron hydrochloride and to evaluate the tablets for various parameters. It was 
planned to carry out this work as outlined below.  
1. To carry out the preformulation studies of API such as  
 Organoleptic properties  
 Solubility 
2. To carry out the drug and excipient compatibility study by FT-IR. 
3. To carry out the pre-compression parameters of the powder blend such as 
 Angle of repose   
 Bulk density 
 Tapped density 
 Compressibility index 
 Hausner’s ratio 
4. To formulate orally disintegrating tablets of Ondansetron HCl by “Direct 
compression method” using various superdisintegrants such as crospovidone, 
sodium starch glycolate and croscarmellose sodium. 
5. To evaluate the compressed tablets for following parameters such as 
 Hardness 
 Thickness 
 Friability 
 Weight variation 
 Wetting time 
 Water absorption ratio 
 In vitro dispersion test 
 Disintegration time 
 Fineness of dispersion 
 Assay 
 In vitro release studies 
6. To perform stability study for the best formulation at 250C ±2 /60% ±5%RH 
and 40
0 
C ±2 /75% ±5%RH for 3 months. 
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CHAPTER - 4 
MATERIALS AND METHODS 
 
4.1. MATERIALS USED AND MANUFACTURERS 
 
Table: 4 List of Materials used and Manufacturers 
 
S.No Materials Manufacturers 
1 
Ondansetron 
hydrochloride 
Mahrshee Laboratories Pvt. Ltd, Gujarat. 
2 
Microcrystalline 
cellulose 
NB Entrepreneurs, Nagpur. 
3 Mannitol 
Qingdao Bright Moon Seaweed Group Co. Ltd, 
China. 
4 Sorbitol Gujarat Ambuja Exports Ltd, Ahmedabad. 
5 Croscarmellose sodium JR Pharma, Gujarat. 
6 Crospovidone Boai NKY Pharmaceuticals Ltd, China. 
7 Sodium starch glycolate Maruti Chemicals, Ahmedabad. 
8 Methyl paraben 
Rasula Pharmaceuticals and Fine Chemicals, 
Hyderabad. 
9 Propyl paraben 
Rasula Pharmaceuticals and Fine Chemicals, 
Hyderabad. 
10 Sucralose The Nutrasweet Co, USA. 
11 Sunset yellow 
Neelikon Food Dyes and Chemicals Limited, 
Mumbai. 
12 Strawberry flavor IFF India Pvt. Ltd, Chennai. 
13 Magnesium stearate 
Par Drugs and Chemicals Pvt. Ltd,                                                      
Vadodara. 
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4.2 DRUG PROFILE 
 
 
DRUG
71
                                             :    Ondansetron hydrochloride
 
 
STRUCTURAL FORMULA     
                                
 
 
:  
 
 
MOLECULAR FORMULA : C18H19N3O.HCl. 2H2O.  
 
MOLECULAR WEIGHT 
 
: 
 
365.90 g/mol. 
 
CHEMICAL NAME 
 
: 
 
 
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3  
dihydro-1H-carbazol-4-one; dihydrate; 
hydrochloride. 
CATEGORY : A competitive serotonin 5-HT3 receptor antagonist. 
pH : 4.5-4.6. 
DESCRIPTION : 
 
A white or almost white powder. 
SOLUBILITY  : 
 
It is sparingly soluble in water and in ethanol; 
soluble in methanol. 
MELTING POINT : 231-232°C. 
DOSE : 
 
4mg, 8mg tablets twice a day for 3-5 days,           
2mg/ml -2ml, 4ml i.v injections ½ an hr 
before chemotherapeutic infusion. 
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PHARMACOKINETICS
72 
 Ondansetron is absorbed from the gastrointestinal tract and undergoes some first 
pass metabolism. Volume of distribution of Ondansetron is 160 ltr. Plasma protein 
binding of Ondansetron is 70-76%. Mean bioavailability in healthy subjects, following 
administration of a single 4 mg tablet, is approximately 56%. Peak plasma 
concentration occurs 1.5 hours after oral administration. Extensively metabolized by 
hepatic cytochrome P450 2D6 isozyme to 9-hydroxyisperidone. Biological half-life is 
5-7 hrs. Excretion via urine; 44-60% as metabolites, 5-10% as unchanged, faeces 
(approximately 25%). 
 
MECHANISM OF ACTION
73 
Ondansetron is a selective serotonin 5-HT3 receptor antagonist. The antiemetic 
activity of the drug is brought through the inhibition of 5-HT3 receptors present both 
centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of          
5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, 
likely indirectly at the level of the area postrema, as well as through direct inhibition of 
serotonin activity within the area postrema and the chemoreceptor trigger zone. 
 
INDICATIONS
74 
Ondansetron HCl is used for the prevention of nausea and vomiting associated with 
the following conditions 
 
 Chemotherapy induced nausea and vomiting 
 Cholestatic pruritus 
 Post-operative nausea and vomiting (PONV) 
 Uremic pruritus 
 Radiation induced nausea and vomiting 
 
TOXICITY 
Low blood pressure, fainting, sudden blindness and severe constipation. 
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DOSAGE AND ADMINISTRATION
75 
  
Adult: 8 mg b.i.d, for up to 5 days after the end of a course of chemotherapy. 
Child: 4-11 year 4 mg 30 minutes prior to chemotherapy; repeat dose at 4 and   
           8
th
 hr after initial dose, then 4 mg  t.i.d for 1 to 2 days after completion  
           of chemotherapy. 
Elderly: No dose adjustment needed. 
 
DRUG INTERACTIONS
76 
CYP3A4 inducers (eg, Phenytoin, Carbamazepine and Rifampicin) may reduce 
the plasma levels of Ondansetron thereby decreasing the antiemetic effect. Concomitant 
use of Tramadol may result in reduced analgesic activity of Tramadol. 
 
CONTRAINDICATIONS
 
The concomitant use of Apomorphine with Ondansetron is contraindicated 
based on reports of profound hypotension and loss of consciousness. Ondansetron 
tablets are contraindicated for patients known to have hypersensitivity to the drug. 
 
ADVERSE REACTIONS 
 
Central Nervous System :      Headache, sedation, dizziness, anxiety.  
 
Dermatologic   :      Pruritus, rash, flushing, urticaria. 
 
Gastro Intestinal Tract :      Constipation, diarrhea, dry mouth, abdominal pain. 
 
Respiratory Tract  :      Hypoxia, bronchospasm. 
 
MARKETED PRODUCTS
77 
Avetron-MD 4mg, Egatron-4 4mg, Vomicard-MD 4mg, Estaset 4 mg, Ondaris 
syrup, Northstar oral solution, Nvest syrup, Vondan injection, Ondax injection. 
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4.3. EXCIPIENTS PROFILE
 
 
4.3.1. MANNITOL
78 
 
NON-PROPRIETARY NAMES   : BP: Mannitol.  
JP: D-Mannitol.  
PhEur: Mannitol.  
USP: Mannitol.      
                                                                                                                                                                                                                     
SYNONYMS     : Cordycepic acid, Emprove, Manna sugar, 
Pearlitol, D-mannite, Mannite, Mannitolum, 
Mannogem.        
                                                                                                                      
CHEMICAL NAME    : D-Mannitol. 
 
 
EMPIRICAL FORMULA 
 
: C6H14O6. 
 
 
 
 
MOLECULAR STRUCTURE 
 
 
 
 
: 
 
MOLECULAR WEIGHT     : 182.17g/mol. 
 
 
MELTING  POINT   : 166-168°C. 
 
 
SOLUBILITY       : Soluble in alkalis and practically insoluble in 
ether. 
 
DESCRIPTION                      : Mannitol occurs as a white, odorless, crystalline 
powder or free-flowing granules.  
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FUNCTIONAL CATEGORY   : Diluent, plasticizer, sweetening agent, tablet 
and capsule diluent, therapeutic agent and 
tonicity agent. 
                                                                                                                                           
APPLICATIONS    : Mannitol is widely used in Pharmaceutical 
formulations and food products. In 
pharmaceutical preparations it is primarily used 
as a diluent (10–90% w/w) in tablet 
formulations. Mannitol may be used in direct-
compression tablet applications, for which the 
granular and spray-dried forms are available 
and also used in wet granulation method.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
STABILITY AND STORAGE 
CONDITIONS 
: Mannitol is stable in the dry state and in 
aqueous solutions. The bulk material should be 
stored in a well-closed container in a cool, dry 
place. 
                                                                                 
INCOMPATIBILITIES    : Mannitol solutions, 20% w/v or stronger, may 
be salted out by potassium chloride or sodium 
chloride. Precipitation has been reported to 
occur when a 25% w/v mannitol solution was 
allowed to contact plastic.  
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4.3.2. SORBITOL 
 
 
NON-PROPRIETARY NAMES
78
   : BP: Sorbitol. 
JP: D-Sorbitol. 
PhEur: Sorbitolum. 
USP-NF: Sorbitol.                                                                                                                                                                                                                     
SYNONYMS     : 1,2,3,4,5,6-hexanehexol, Liponic 70-NC, 
Meritol, Neosorb, Sorbite, D-sorbitol, 
Sorbitol Instant, Sorbogem.  
                                                                                                                    
CHEMICAL NAME    : D- Glucitol. 
 
EMPIRICAL FORMULA 
 
: C6H14O6. 
MOLECULAR STRUCTURE   : 
   
 
MOLECULAR WEIGHT
79
     : 182.17 g/mol. 
 
MELTING  POINT   : 110–112
o
 C. 
 
SOLUBILITY       : Practically insoluble in chloroform and 
ether, slightly soluble in methanol. 
 
DESCRIPTION                      : Sorbitol is D- glucitol. It is a hexahydric 
alcohol related to mannose and is isomeric 
with mannitol. Sorbitol occurs as an 
odorless, white or almost colorless, 
crystalline, hygroscopic powder. 
 
FUNCTIONAL CATEGORY   : Humectant, plasticizer, sweetening agent, 
tablet and capsule diluent. 
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APPLICATIONS    : Sorbitol is widely used as an excipient in 
pharmaceutical formulations. It is also 
used extensively in cosmetics and food 
products. It is particularly useful in 
chewable tablets owing to its pleasant, 
sweet taste and cooling sensation. 
 
STABILITY AND STORAGE 
CONDITIONS 
: Sorbitol is stable in air, dilute acids and 
alkalis. The bulk material is hygroscopic 
and should be stored in an airtight 
container in a cool, dry place. 
 
INCOMPATIBILITIES    : Sorbitol will form water-soluble chelates 
with many divalent and trivalent metal 
ions in strongly acidic and alkaline 
conditions. Addition of liquid polyethylene 
glycols to sorbitol solution, with vigorous 
agitation, produces a waxy, water-soluble 
gel with a melting point of 35–40OC. 
Sorbitol solutions also react with iron 
oxide to become discolored. Sorbitol 
increases the degradation rate of 
Penicillins in neutral and aqueous 
solutions.                                                                                                                                                                                                                                                                                                                                                                                                                                                           
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4.3.3. MICROCRYSTALLINE CELLULOSE
80 
 
NON-PROPRIETARY NAMES   : BP: Microcrystalline cellulose. 
JP: Microcrystalline cellulose. 
PhEur: Cellulosum microcrystallinum. 
USP-NF: Microcrystalline cellulose. 
 
SYNONYMS     : Avicel PH, Cellulose gel, Celphere, Crystalline 
cellulose, Emcocel, Ethispheres, Fibrocel, 
Pharmacel. 
 
CHEMICAL NAME    : Cellulose. 
 
 
EMPIRICAL FORMULA 
 
: (C6H10O5)n. 
 
 
 
MOLECULAR STRUCTURE 
    
: 
 
 
 
 
MOLECULAR WEIGHT     
 
  
: 
  
Approximately 36000. 
 
 
MELTING  POINT
78
 : Melts at 260- 270
0
C. 
 
 
SOLUBILITY       : Slightly soluble in 5% w/v sodium hydroxide 
solution; practically insoluble in water, dilute 
acids and most organic solvents. 
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DESCRIPTION                      : Microcrystalline cellulose is purified, partially 
depolymerized cellulose that occurs as a white, 
odorless, tasteless, crystalline powder 
composed of porous particles. 
 
FUNCTIONAL CATEGORY   : Adsorbent, suspending agent, diluent and tablet 
disintegrant.                    
                                                                                                                       
APPLICATIONS    : Microcrystalline cellulose is widely used in 
pharmaceuticals, primarily as a binder/diluent 
in oral tablet and capsule formulations where it 
is used in both wet-granulation and direct-
compression processes. In addition to its use as 
a binder/diluent, microcrystalline cellulose also 
has some lubricant and disintegrant properties 
that make it useful in tableting. Microcrystalline 
cellulose is also used in cosmetics and food 
products. 
 
STABILITY AND STORAGE 
CONDITIONS 
: It should be stored at room temperature in well-
closed containers under dry and odor- free 
conditions. 
 
INCOMPATIBILITIES    : Microcrystalline cellulose is incompatible with 
strong oxidizing agents. 
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4.3.4. SODIUM STARCH GLYCOLATE
81 
 
NON-PROPRIETARY NAMES   : BP: Sodium starch glycolate. 
PhEur: Carboxy methylamylum natricum. 
USP-NF: Sodium starch glycolate. 
  
SYNONYMS     : Carboxymethyl starch, Sodium salt, Explosol, 
Glycolys, Primojel, Starch carboxymethyl ether.    
                                                  
                             
CHEMICAL NAME    : Sodium carboxy methyl starch. 
 
 
EMPIRICAL FORMULA 
 
: C2H4O3. 
 
 
 
MOLECULAR STRUCTURE 
 
: 
 
 
 
MOLECULAR WEIGHT     
 
: 
 
98.033 g/mol. 
 
 
MELTING  POINT   : Does not melt but chars at 200
o
C. 
 
 
SOLUBILITY
78
       : Sparingly soluble in ethanol (95%), practically 
insoluble in water.  
 
DESCRIPTION                      : Sodium starch glycolate is a white to off-white, 
odorless, tasteless, free-flowing powder. 
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FUNCTIONAL CATEGORY   :  Tablet and capsule disintegrant. 
              
                                         
APPLICATIONS    : Sodium starch glycolate is widely used in oral 
pharmaceuticals as a disintegrant in capsule and 
tablet formulations. Sodium starch glycolate has 
also been investigated for use as a suspending 
vehicle. 
 
 
STABILITY AND STORAGE 
CONDITIONS 
: Sodium starch glycolate is stable and should be 
stored in a well closed container to protect it from 
wide variations in humidity and temperature that 
may cause caking. 
 
 
INCOMPATIBILITIES    : Sodium starch glycolate is incompatible with 
ascorbic acid.                                                                                                                                                                                                                                                                                                                                                                                                                                                           
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4.3.5. CROSCARMELLOSE SODIUM
82 
 
NON-PROPRIETARY NAMES   : BP: Croscarmellose sodium. 
PhEur: Croscarmellose sodium. 
USP-NF: Croscarmellose sodium. 
 
SYNONYMS     : Ac-Di-Sol, Crosslinked carboxy methylcellulose 
sodium, Modified cellulose gum, Primellose, 
Solutab, Vivasol. 
                                                                                                                     
CHEMICAL NAME    : Carboxymethyl ether, Sodium salt crosslinked. 
 
 
EMPIRICAL FORMULA 
 
: C28H30Na8O27. 
 
MOLECULAR STRUCTURE 
 
: 
 
 
 
MOLECULAR WEIGHT     : 90,000–700,000. 
 
 
MELTING  POINT   : More than 205
0
C. 
 
 
SOLUBILITY 
78
      : Insoluble in water, although croscarmellose 
sodium rapidly swells to 4–8 times its original 
volume on contact with water. Practically 
insoluble in acetone, ethanol and toluene. 
 
DESCRIPTION                      : Croscarmellose sodium occurs as an odorless, 
white colored powder. 
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FUNCTIONAL CATEGORY   : Tablet and capsule disintegrant. 
                                                                                                                                          
APPLICATIONS    : Croscarmellose sodium is used in oral 
pharmaceutical formulations as a disintegrant for 
capsules, tablets and granules. In tablet 
formulations, croscarmellose sodium may be used 
in both direct-compression and wet-granulation 
processes. Croscarmellose sodium at 
concentrations up to 5% w/w may be used as a 
tablet disintegrant, although normally 2% w/w is 
used in tablets prepared by direct compression and 
3% w/w in tablets prepared by a wet-granulation 
process. 
 
STABILITY AND STORAGE 
CONDITIONS 
: Croscarmellose sodium is a stable though 
hygroscopic material. It should be stored in well 
closed container. 
 
INCOMPATIBILITIES    : The efficacy of croscarmellose sodium may be 
slightly reduced in tablet formulations prepared by 
either wet granulation or direct compression 
process which contains hygroscopic excipients 
such as sorbitol.                                                                                                                                                                                                                                                                                                                                                                                                                                                          
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4.3.6. CROSPOVIDONE
83 
 
NON-PROPRIETARY NAMES   : BP: Crospovidone. 
PhEur: Crospovidonum. 
USP-NF: Crospovidone. 
 
SYNONYMS     : Crosslinked povidone, Kollidon CL, 
Kollidon CL-M, Polyplasdone XL, 
Polyvinylpolypyrrolidone. 
                                                                                                                     
CHEMICAL NAME    : 1-Ethenyl-2-pyrrolidinone homopolymer. 
 
 
EMPIRICAL FORMULA 
 
: (C6H9NO)n. 
 
MOLECULAR STRUCTURE   :  
 
 
MOLECULAR WEIGHT     : 2.5 g/mol. 
 
 
MELTING  POINT   : 150
0
C. 
 
SOLUBILITY       : Practically insoluble in water and most 
common organic solvents. 
 
DESCRIPTION                      : Crospovidone is a white to creamy-white, 
finely divided, free-flowing, practically 
tasteless, odorless or nearly odorless, 
hygroscopic powder. 
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FUNCTIONAL CATEGORY   : Tablet disintegrant. 
                                                                                                                              
APPLICATIONS 
78
   : Crospovidone is used as tablet disintegrant 
at 2–5% concentration in tablets prepared 
by direct-compression or wet- and dry-
granulation methods. Crospovidone can 
also be used as a solubility enhancer. 
 
STABILITY AND STORAGE 
CONDITIONS 
: Crospovidone is a hygroscopic material. So 
it should be stored in an airtight container 
in a cool, dry place. 
 
INCOMPATIBILITIES    : Crospovidone is compatible with most 
organic and inorganic Pharmaceutical 
ingredients. When exposed to a high water 
level, crospovidone may form molecular 
adduct with some materials.                                                                                                                                                                                                                                                                                                                                                                                                                                                       
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4.3.7. METHYL PARABEN
84 
 
NON-PROPRIETARY NAMES   : BP: Methyl hydroxybenzoate. 
JP: Methyl parahydroxybenzoate. 
PhEur: Methyl parahydroxybenzoate. 
USP-NF: Methylparaben. 
 
SYNONYMS     : 4-Hydroxybenzoic acid methyl ester, Methyl 
p-hydroxybenzoate, Nipagin M.    
                                                                                                                  
CHEMICAL NAME    : Methyl-4-hydroxy benzoate.  
 
EMPIRICAL FORMULA 
 
: C8H8O3. 
MOLECULAR STRUCTURE   
: 
  
 
 
MOLECULAR WEIGHT     : 152.15 g/mol. 
 
 
MELTING  POINT   : 125–128
0
 C. 
 
 
SOLUBILITY       : Soluble in acetone, alcohol and in water 
when heated. 
 
DESCRIPTION                      : Methylparaben occurs as colorless crystals 
or a white crystalline powder. It is odorless 
or almost odorless and has a slight burning 
taste. 
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FUNCTIONAL CATEGORY   : Antimicrobial preservative.   
                                                                                                                     
APPLICATIONS
78
    : Methylparaben is widely used as an 
antimicrobial preservative in cosmetics, food 
products and pharmaceutical formulations. 
 
STABILITY AND STORAGE 
CONDITIONS 
: Aqueous solutions of methylparaben at      
pH 3–6 may be sterilized by autoclaving at 
120
0
C for 20 minutes, without 
decomposition. Methylparaben should be 
stored in a well-closed container in a cool, 
dry place. 
 
INCOMPATIBILITIES    : The antimicrobial activity of methylparaben 
is considerably reduced in the presence of 
nonionic surfactants, such as polysorbate 80, 
as a result of micellization. Methylparaben is 
discolored in the presence of iron and is 
subjected to hydrolysis by weak alkalis and 
strong acids. 
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4.3.8. PROPYL PARABEN
85 
 
NON-PROPRIETARY NAMES   : BP: Propyl hydroxybenzoate. 
JP: Propyl parahydroxybenzoate. 
PhEur: Propyl parahydroxybenzoate. 
USP-NF: Propylparaben. 
 
SYNONYMS     : 4-Hydroxybenzoic acid propyl ester, Nipasol M, 
Propyl p-hydroxybenzoate, Propyl parasept, 
Solbrol P. 
 
CHEMICAL NAME    : Propyl 4-hydroxybenzoate. 
 
 
EMPIRICAL FORMULA 
 
: C10H12O3. 
MOLECULAR STRUCTURE  :  
 
 
 
MOLECULAR WEIGHT     : 180.20 g/mol. 
 
 
MELTING  POINT   : 96-99
o
C. 
 
 
SOLUBILITY       : Soluble in acetone, alcohol and in water when 
heated. 
 
DESCRIPTION                      : Propylparaben occurs as a white, crystalline, 
odorless and tasteless powder. 
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FUNCTIONAL CATEGORY   : Antimicrobial preservative. 
                                                                                                                                           
APPLICATIONS
78
    : Propylparaben is widely used as an antimicrobial 
preservative in cosmetics, food products and 
Pharmaceutical formulations. 
 
STABILITY AND STORAGE 
CONDITIONS 
: Propylparaben is stable under normal conditions 
and decomposes on heating. It should be stored 
in a tightly closed container. 
 
INCOMPATIBILITIES    : The activity of propylparaben can be adversely 
affected by the presence of other excipients or 
active ingredients, such as atropine, essential 
oils, iron, magnesium trisilicate, talc, 
polysorbate and other nonionic surfactants, 
sorbitol, weak alkalis and strong acids.                                                                                                                                                                                                                                                                                                                                                                                                                                                         
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4.3.9. SUCRALOSE
78 
 
NON-PROPRIETARY NAMES   : USP-NF: Sucralose. 
  
SYNONYMS     : Sucralose, Sucralosum, Sucra plus. 
                                                                                                                     
CHEMICAL NAME    : 1,6-Dichloro-1,6-dideoxy-β-D-fructofuranosyl  
-4-chloro-4-deoxy-α-D-galactopyranoside. 
 
EMPIRICAL FORMULA 
 
: C12H19Cl3O8. 
MOLECULAR STRUCTURE    
: 
 
 
 
 
MOLECULAR WEIGHT     : 397.64 g/mol. 
 
 
MELTING  POINT   : 130
0
C. 
 
SOLUBILITY       : Freely soluble in ethanol (95%), methanol and 
water. Slightly soluble in ethyl acetate. 
 
DESCRIPTION                      : Sucralose is a white to off-white colored, free-
flowing, crystalline powder. 
 
FUNCTIONAL CATEGORY   : Sweetening agent. 
 
APPLICATIONS    : Sucralose is used as a sweetening agent in 
beverages, foods and Pharmaceutical 
applications.  
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STABILITY AND STORAGE 
CONDITIONS 
: Sucralose is a relatively stable material. In 
aqueous solution, at highly acidic conditions 
(pH < 3) and at high temperature, it is 
hydrolyzed to a limited extent, producing 4-
chloro-4-deoxygalactose and 1,6-dichloro-1,6-
dideoxyfructose. It should be stored in a well 
closed container in a cool, dry place, at a 
temperature of not exceeding 21
0
C. 
 
INCOMPATIBILITIES : It alters process in the gut, this can limit the 
absorption and thus the effectiveness of life- 
saving therapeutic drugs, including the drugs 
used for cancer and heart disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                         
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4.3.10. SUNSET YELLOW FCF
86 
 
SYNONYMS     : Orange yellow S, FD& C yellow, E110.   
                                                                                                                  
CHEMICAL NAME    : Disodium 6-hydroxy-5-[(4-sulfophenyl) 
azo]-2-naphthalenesulfonate. 
                                                     
                                                                                                                                                                                                                                                                                                                                                                                            
EMPIRICAL FORMULA 
 
: C16H10N2Na2O7S2. 
 
 
 
 
MOLECULAR STRUCTURE  : 
 
 
 
MOLECULAR WEIGHT     : 452.37 g/mol. 
 
 
MELTING  POINT   : 300
0
C. 
 
 
 
SOLUBILITY       : Soluble in water, sparingly soluble in 
ethanol. 
 
 
DESCRIPTION                      : Reddish yellow powder. Aqueous solutions 
are bright orange colored. 
 
 
FUNCTIONAL CATEGORY   : Coloring agent. 
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APPLICATIONS
87
    : Sunset yellow is used as coloring agent in 
food, cosmetics and pharmaceuticals. For 
example, it is used in candy, desserts, 
snacks, sauces and preserved fruits. Sunset 
yellow is often used in conjunction with 
E123, amaranth to produce a brown color 
in both chocolates and caramel. 
 
STABILITY AND STORAGE 
CONDITIONS 
: Sunset yellow is sensitive to light. So it 
should be stored at room temperature in a 
well closed light resistant container. 
 
INCOMPATIBILITIES    : It is poorly compatible with citric acid, 
saccharose solutions and saturated sodium 
bicarbonate solutions. Incompatible with 
ascorbic acid, gelatin and glucose. 
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4.3.11. MAGNESIUM STEARATE
78 
 
NON-PROPRIETARY NAMES   : BP: Magnesium stearate. 
JP: Magnesium stearate. 
PhEur: Magnesii stearas. 
USP-NF: Magnesium stearate. 
 
SYNONYMS     : Magnesium octadecanoate, Octadecanoic 
acid, Stearic acid and Magnesium salt. 
                                                                                                     
CHEMICAL NAME    : Octadecanoic acid magnesium salt. 
 
 
EMPIRICAL FORMULA 
 
: C36H70MgO4. 
 
MOLECULAR STRUCTURE 
  
  : 
 
 
MOLECULAR WEIGHT     : 591.34 g/mol. 
 
 
MELTING  POINT   : 117-150
0
C. 
 
 
SOLUBILITY       : Practically insoluble in ethanol, ether and 
waters. Slightly soluble in warm benzene 
and warm ethanol. 
 
DESCRIPTION                      : Magnesium stearate is a very fine, light 
white, precipitated or milled, impalpable 
powder of low bulk density, having a faint 
odor and a characteristic taste. 
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FUNCTIONAL CATEGORY   : Tablet and capsule lubricant. 
                                                                                                                                        
APPLICATIONS    : Magnesium stearate is widely used in 
cosmetics, foods and Pharmaceutical 
formulations. It is primarily used as a 
lubricant in capsule and tablet manufacture 
at a concentration between 0.25% and 
5.0% w/w. It is also used in barrier creams. 
 
STABILITY AND STORAGE 
CONDITIONS 
: Magnesium stearate is stable under 
ordinary conditions. It should be stored in a 
well closed container in a cool dry place. 
 
INCOMPATIBILITIES    :  It is incompatible with strong acids, alkalis 
and iron salts. It cannot be used in products 
containing aspirin, vitamins and alkaloidal 
salts.                                                                                                                                                                                                                                                                                                                                                                                                                                                          
 
  
 
 
 
List of Instruments 
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4.4. INSTRUMENTS USED AND MANUFACTURERS 
 
Table: 5 List of Instruments used and Manufacturers 
 
S. No. Instruments Manufacturers 
1 Single pan Electronic Balance Sartorius AG, Germany. 
2 
12 Station D/B Tooling Compression 
Machine 
Fluid Pack, Ahmedabad.  
3 Vernier Caliper Mitutoyo Corporation, Japan. 
4 Dissolution Test Apparatus Electro Lab India Pvt. Ltd, Mumbai. 
5 Hardness Tester Campbell Electronics, Mumbai. 
6 Friability Test Apparatus Electro Lab India Pvt. Ltd, Mumbai. 
7 Standard Sieves Jayant Scientific Industries, Mumbai. 
8 Disintegration Test Apparatus Electro Lab India Pvt. Ltd, Mumbai. 
9 FT-IR Spectrophotometer Shimadzu, Japan. 
10 HPLC Waters Corporation, USA. 
11 Stability Chamber Labtop House, Mumbai. 
12 Blister Packing Machine Elmach Packages Pvt. Ltd, Mumbai. 
 
 
 
  
 
 
Methodology 
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4.5. METHODOLOGY 
 
4.5.1. CALIBRATION CURVE OF ONDANSETRON HYDROCHLORIDE
88 
 
Preparation of 0.1M Hydrochloric Acid 
Place 8.5 ml of concentrated hydrochloric acid into the 1000 ml volumetric 
flask and the volume were made up with de-mineralized water. 
 
Preparation of Mobile Phase 
0.05 M Potassium dihydrogen phosphate buffer (pH 4.5 ± 0.05): Acetonitrile: 
Methanol were mixed in the ratio of 50:40:10.  
 
Calibration Curve of Ondansetron Hydrochloride  
100 mg of Ondansetron hydrochloride was dissolved in 100ml of               
0.1M hydrochloric acid and further dilutions were made using the same solution to 
obtain concentrations ranging from 1µg/ml to 10µg/ml. The peak areas of the each 
dilutions were measured at 248 nm by HPLC method. The obtained peak areas against 
each dilution levels are shown in Table: 6 and the concentration versus peak area is 
plotted in a graph which is shown in Fig: 5. 
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Table: 6 Standard Calibration Curve Data of Ondansetron Hydrochloride  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 5 Standard Calibration Curve of Ondansetron Hydrochloride 
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Concentration (µg/ml) 
S.NO. Concentration (µg/ml) Peak Area (mAU) 
1 1 241310 
2 2 482580 
3 3 723910 
4 4 965260 
5 5 1206590 
6 6 1447860 
7 7 1689178 
8 8 1930480 
9 9 2171800 
10 10 2413100 
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4.5.2. PREFORMULATION STUDIES
89 
Preformulation can be defined as an investigation of physical and chemical 
properties of drug substance alone and when combined with excipients. It is the first 
step in the rational development of dosage forms. The overall objective of 
preformulation testing is to generate information useful to the formulator in 
developing stable and bioavailable dosage forms. The use of preformulation 
parameters maximizes the chances in formulating acceptable, safe, efficacious and 
stable product.   
 
4.5.2.1. ORGANOLEPTIC PROPERTIES 
 The organoleptic properties like color, odor and taste of the API was 
evaluated. 
a) Color: A small quantity of Ondansetron HCl was taken in a butter paper and 
viewed in well-illuminated place.  
b) Taste and odor: Very less quantity of Ondansetron HCl was used to assess the 
taste with the help of tongue as well as smelled to get odor.  
 
4.5.2.2. SOLUBILITY TEST
90 
 Solubility of Ondansetron hydrochloride in water, methanol and ethanol was 
determined by using Sonicator at room temperature. Approximate solubility of drugs 
as per B.P was indicated in table: 7. 
Table: 7. Solubility Specification of Drugs 
Solubility 
Approximate Volume of 
Solvent in ml per gm of Solute 
Very soluble Less than 1 
Freely soluble 1 to 10 
Soluble 10 to 30 
Sparingly soluble 30 to 100 
Slightly soluble 100 to 1000 
Very slightly soluble 1000 to 10000 
Practically insoluble/ Insoluble More than 10000 
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4.5.2.3. DRUG: EXCIPIENT COMPATIBILITY STUDIES 
 Compatibility studies were performed by preparing blend of different 
excipients with drug and stored at 40
O
C±2
O
C /75±5%RH for one month. The blend 
were evaluated for every 15 days for changes like caking, liquefaction, discoloration 
and odor formation. The drug excipient compatibility studies were shown in table: 8. 
 
Table: 8 Drug : Excipients Compatibility Protocol 
S. No. Drug and Excipients 
Ratio 
(Drug:Excipient) 
 
1 Ondansetron HCl 1 
2 Ondansetron HCl + Mannitol (anhydrous) 
1:1 
 
3 Ondansetron HCl + Sorbitol (granular grade) 
1:1 
 
4 
Ondansetron HCl + Microcrystalline cellulose 
(MCC-112) 
1:1 
5 Ondansetron HCl + Sodium starch glycolate 
1:1 
 
6 Ondansetron HCl + Croscarmellose sodium 
1:1 
 
7 Ondansetron HCl + Crospovidone 
1:1 
 
8 Ondansetron HCl + Methylparaben 
1:1 
 
9 Ondansetron HCl + Propylparaben 
1:1 
 
10 Ondansetron HCl + Sucralose 
1:1 
 
11 Ondansetron HCl + Sunset yellow FCF 
1:0.5 
 
12 Ondansetron HCl + Strawberry flavor 
1:0.5 
 
13 Ondansetron HCl + Magnesium stearate 
1:1 
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4.5.3. FT-IR STUDIES
91 
Infrared spectra matching approach was used for the detection of any possible 
chemical reaction between the drug and the excipients.  A physical mixture (1:1) of 
drug and excipients was prepared and mixed with suitable quantity of potassium 
bromide. About 100 mg of this mixture was compressed to form a transparent pellet 
using a hydraulic press at 10 tons pressure.  It was scanned between 4000- 500 cm
-1 
in 
a shimadzu FT-IR spectrophotometer.  The IR spectrum of the physical mixture was 
compared with those of pure drug and excipients and matching was done to detect any 
appearance or disappearance of peaks.  
 
4.5.4. EVALUATION OF PRECOMPRESSION PARAMETERS 
 
4.5.4.1. MICROMERITIC PROPERTIES 
 
4.5.4.1.1. ANGLE OF REPOSE
92, 93 
Angle of repose is defined as the maximum angle that can be obtained 
between the surface of a powder heap and the horizontal plane. Angle of repose has 
been used as an indirect method of quantifying powder flowability, because of their 
relationship with interparticle cohesion.  
The angle of repose was determined by funnel method. The funnel was fixed 
at a particular height ‘h’ on a burette stand. A graph paper was placed below the 
funnel on the table. The powder blend whose angle of repose is to be determined was 
passed slowly through the funnel, until if forms a pile. Further addition of powder 
blend was stopped as soon as the pile touches the tip of the funnel. Circumference of 
the pile of powder blend was drawn with a pencil without disturbing the pile. The 
radius of the pile ‘r’ was noted. Flow properties and corresponding angle of repose as 
per I.P Table: 9. Angle of repose of the powder blend was calculated by using the 
following formula, 
tanθ = h/r 
   θ = tan-1 (h/r) 
Where, 
 θ = Angle of repose 
 h = Height of the pile. 
 r = Radius of the pile.  
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Table: 9 Flow Properties and Corresponding Angle of Repose as per I.P 
 
Flow Property Angle of Repose 
Excellent 25 – 30 
Good 31 – 35 
Fair 36 – 40 
Passable 41 – 45 
Poor 46 – 55 
Very poor 56 – 65 
Very very poor > 66 
 
 
4.5.4.1.2. BULK DENSITY
94, 95 
Bulk density is defined as powder mass divided by its bulk volume without 
any tapping. Powder bulk density depends primarily on particle size distribution, 
particle shape and the tendency of particles adhere to each other. Some particles may 
pack loosely, leading to fluffy and light weight powder, while others may contain 
smaller particles that sift between larger particles to fill the void, leading to dense and 
heavy powder. Bulk density is often used to calculate the batch size for blender and 
granulator. 
Weighed quantity of powder blend from each formulation was taken in a      
50 ml measuring cylinder and the initial volume of the powder blend in the measuring 
cylinder was noted. Bulk density of the powder blend was calculated by using the 
formula, 
  
   ρb = M/ Vb 
Where, 
 ρb = Bulk density, 
 M = Weight of the sample in gm, 
 Vb = Final volume of the powder blend in cm
3
. 
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4.5.4.1.3. TAPPED DENSITY 
 Tapped density of the powder is the ratio of the mass of the powder to the 
volume occupied by the powder after it has been tapped for a defined period of time. 
Tapped density was measured by introducing the known quantity of the powder into a 
graduated cylinder and carefully leveling off the powder without compacting it. The 
graduated cylinder was mechanically tapped by placing on the bulk density apparatus. 
The volume was measured by tapping the powder blend for 500 times. Then the 
tapping was done for 750 times and the tapped volume was noted. The tapped density 
was calculated by using the formula, 
    
ρt = M/ Vt 
Where, 
 ρt = Tapped density, 
 M = Weight of the sample in gm, 
 Vt = Tapped volume of the powder blend in cm
3
. 
 
4.5.4.1.4. COMPRESSIBILITY INDEX
96
 
The compressibility index is measure of the propensity of a powder to 
consolidate. As such, it is a measure of the relative importance of inter-particulate 
interactios. In a free-flowing powder, such interactions are generally less significant 
and the bulk and tapped densities will be closer in value. For poorer flowing 
materials, there are frequently greater interparticle interactions bridging between 
particles often results in lower bulk density and a greater difference between the bulk 
and tapped densities. These differences in particle interactions are reflected in the 
compressibility index. Compressibility index was calculated from the bulk and tapped 
density using the following formula, 
 
Compressibility index(%)  =  [
𝑇𝐷 – 𝐵𝐷
𝑇𝐷
 ] × 100 
Where, 
 TD = Tapped density 
 BD = Bulk density 
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4.5.4.1.5. HAUSNER’S RATIO 
 The Hausner’s ratio is a number that is correlated to the flowability of a 
powder or granular material. Hausner’s ratio was calculated from the bulk and tapped 
density using the following formula,  
 
Hausner’s ratio = 
𝑇𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝐵𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
 
 
 Table: 10 Scale of Flowability 
Flow Character Compressibility Index (%) Hausner’s Ratio 
Excellent <10 1.00 – 1.11 
Good 11 – 15 1.12 – 1.18 
Fair 16 – 20 1.19 – 1.25 
Passable 21 – 25 1.26 – 1.34 
Poor 26 – 31 1.35 – 1.45 
Very poor 32 – 37 1.46 – 1.59 
Extremely poor >38 >1.60 
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4.5.5. FORMULATION OF ONDANSETRON HYDROCHLORIDE ORALLY 
DISINTEGRATING TABLETS BY DIRECT COMPRESSION METHOD 
Orally disintegrating tablets of Ondansetron hydrochloride were prepared by 
direct compression method as per the composition shown in Table: 11. Seven 
formulations (F-I to F-VII) were prepared by direct compression method. 
 
DIRECT COMPRESSION METHOD  
 
Sieving 
The active ingredient was passed through the sieve # 40. The other 
ingredients given in the formulation table were passed separately through the 
same sieve.  
Dry mixing        
All the materials (including the active ingredient) were taken in poly 
bag and mixed for 10 minutes.  
Lubrication  
The magnesium stearate was passed through the sieve # 60 and mixed 
together with the powder mixture in a polybag for 5 minutes to get a uniform 
blend. 
Compression  
Finally, the powder mixture was compressed into tablets using rotary 
tablet compression machine of punch size 7.14mm to prepare tablets each 
weighing 140mg. 
Packing  
The prepared tablets were packed by using PVC-Alu Blister packing. 
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FORMULATION FLOWCHART OF DIRECT COMPRESSION METHOD 
 
 
 
  
 
 
 
 
 
 
 
 
     
      
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
STEPS 
SIEVING 
 
DRY MIXING 
 
LUBRICATION 
 
COMPRESSION 
All the ingredients 
were passed through 
sieve # 40 
Mixed for 10 minutes 
in polybag 
Magnesium stearate was 
passed through sieve # 60 
and mixed with powder 
blend for 5 minutes.  
The powder mixture was 
compressed into tablets using 
rotary tablet compression 
machine of 7.14 mm punch 
and die. 
PACKING 
The compressed tablets were 
packed in PVC-Alu Blister 
packing.  
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Table: 11 Composition of Ondansetron Hydrochloride Orally Disintegrating 
Tablets  
 
 
Ingredients 
 
Quantity per Tablet (mg) 
Formulation Code 
F-I F-II F-III F-IV F-V F-VI F-VII 
Ondansetron 
hydrochloride   
4.00 4.00 4.00 4.00 4.00 4.00 4.00 
Mannitol (anhydrous) 116.80 116.80 116.80 - - - 70.08 
Sorbitol (granular grade) - - - 116.80 116.80 116.80 - 
Microcrystalline cellulose 
(MCC-112) 
      46.72 
Sodium starch glycolate 14.00 - - 14.00 - - - 
Croscarmellose sodium - 14.00 - - 14.00 - - 
Crospovidone - - 14.00 - - 14.00 14.00 
Methylparaben 0.80 0.80 0.80 0.80 0.80 0.80 0.80 
Propylparaben 0.20 0.20 0.20 0.20 0.20 0.20 0.20 
Sucralose  1.40 1.40 1.40 1.40 1.40 1.40 1.40 
Sunset yellow FCF 0.70 0.70 0.70 0.70 0.70 0.70 0.70 
Strawberry flavor 1.40 1.40 1.40 1.40 1.40 1.40 1.40 
Magnesium stearate 0.70 0.70 0.70 0.70 0.70 0.70 0.70 
Weight of each Tablets  140 140 140 140 140 140 140 
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4.5.6. POST COMPRESSION PARAMETERS 
 The compressed tablets were evaluated for the following parameters. 
 
4.5.6.1. GENERAL APPEARANCE  
 The tablet should be free from cracks, depressions, pinholes etc. The color and 
polish of the tablets should be uniform on whole surface. The surface of the tablets 
should be smooth. The tablets were examined externally under a biconvex lens for 
surface cracks, depression and pinholes. 
 
4.5.6.2. HARDNESS TEST
97 
Tablet requires a certain amount of mechanical strength to withstand the shock 
of handling in its manufacture, packaging, shipping and dispensing. It may be 
especially important to monitor the tablet hardness for sustained release drug products 
or other products that possess real or potential bioavailability problems or sensitive to 
variations in drug release profile.  
The crushing strength that just causes the tablet to break is recorded by means 
of Monsanto hardness tester.  The tablet is placed vertically in between the lower and 
upper plungers.  The initial reading was taken immediately after placing the tablet 
onto the lower plunger. The upper plunger was then forced against a spring by turning 
a threaded bolt until the tablet gets fractured. As the spring was compressed, a point 
moves along a gauge in the barrel to indicate pressure.  The position of the pointer at 
the time of tablet fracture was noted and the difference between the initial and the 
final readings was noted as hardness of the tablet. The value was expressed in 
Kg/cm
2
. 
 
4.5.6.3. THICKNESS  
The thickness of the individual tablets was measured by using Vernier caliper 
and average thickness is determined. The thickness was denoted in millimeter. 
 
 
 
 
 
Chapter-4                                                                              Methodology 
 
S.B.C.P                           Department of Pharmaceutics Page 84 
 
4.5.6.4. WEIGHT VARIATION TEST
98 
Twenty tablets were selected at random and its individual weight was noted 
and from that, the mean weight of the tablets was calculated. Not more than two of the 
individual weights deviate from the average weight by more than the percentage 
deviation shown in table: 12 and none should deviate by more than twice that 
percentage. 
 
Table: 12 Weight Variation of Tablets and Percentage Deviation 
Average Weight of Tablets(mg) 
in I.P 
Percentage Deviation 
(%)  
130 or less ±10 
130 – 324 ±7.5 
More than 324 ±5 
 
 
4.5.6.5. FRIABILITY
99 
Friability is the measure of tablet’s ability to withstand both shock and 
abrasion without crumbling during manufacturing, packing, shipping and consumer 
use. Tablets that tend to powder, chip and fragment when handled lack elegance and 
hence consumer acceptance.   
The weight of 10 tablets was noted and placed in Roche friabilator. The device 
subjects the tablets to the combined effect of shock and abrasion by utilizing a plastic 
chamber which revolves at 25 rpm, rolling the tablets a distance of 6 inches with the 
revolution. The tablets were removed after 100 revolutions, dedusted and reweighed. 
Tablets that loose less than 0.5 to 1 percent in weight are generally acceptable. The 
percentage friability of the tablets were calculated by the formula,   
 
Percentage Friability = 
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑊𝑒𝑖𝑔ℎ𝑡−𝐹𝑖𝑛𝑎𝑙 𝑊𝑒𝑖𝑔ℎ𝑡
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑊𝑒𝑖𝑔ℎ𝑡
x 100 
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4.5.6.6. DISINTEGRATION TEST
100 
 Disintegration test was carried out at 37
0
C±2
0
C in 900 ml of distilled water. 
The disintegration time of tablets from each formulations were determined using 
disintegration test apparatus. One tablet was placed in each of the six tubes of the 
apparatus containing distilled water. One disk was added to each tube. The time taken 
in seconds for complete disintegration of the tablets with no palpable mass remaining 
in the apparatus was measured. 
 
4.5.6.7. WETTING TIME AND WATER ABSORPTION RATIO
101
  
A piece of tissue paper folded twice was placed in a small petri dish of 6.5cm 
in diameter containing 6ml of water. A preweighed tablet was placed on the surface of 
tissue paper and allowed to completely wet. The time required for water to reach the 
upper surface of the tablet and to completely wet it was noted as the wetting time. The 
wetted tablet was then weighed. Water absorption ratio (R) was determined using the 
following equation, 
 
R =  
Wa−Wb
Wb
𝑋 100  
Where, 
Wb - Weight of tablet before wetting. 
Wa - Weight of tablet after wetting. 
  
4.5.6.8. IN VITRO DISPERSION TIME
102 
Tablet was placed in a small petri dish containing 10ml of water and time 
required for the complete dispersion of tablet was determined. 
 
4.5.6.9. FINENESS OF DISPERSION
103
 
The fineness of dispersion test was done by using two tablets in 100ml of 
water and stir gently until completely dispersed. The smooth dispersion obtained was 
passed through a sieve screen with a nominal mesh aperture of 710mm (Sieve #22). 
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4.5.6.10. ASSAY OF ONDANSETRON HCl BY HPLC METHOD
71 
 
Chromatographic Conditions: 
Column             : LICHROSPHER , CN, 250 × 4.6mm.  
Mobile phase  : 52 ml buffer solution, 48 ml Acetonitrile (ACN). 
Buffer                         : 0.272% w/v solution of monobasic potassium 
phosphate. Adjust to pH 5.4 with 1M sodium 
hydroxide. 
Flow rate  : 1.5 ml/minute. 
Injection volume : 10 µl. 
Wavelength  : 248 nm. 
Temperature  : 30°C. 
 
Preparation of Mobile Phase 
 Buffer and ACN were mixed in the ratio of 52:48. The pH of the mobile phase 
was adjusted to 5.4. 
 
Preparation of Standard Solution 
0.004% w/v solution of Ondansetron reference standard in 0.1M hydrochloric 
acid. 
 
Preparation of Sample Solution 
20 tablets were weighed and powdered. The powder equivalent to 40mg of 
Ondansetron was dissolved in 100 ml of 0.1M hydrochloric acid. 1.0 ml of this 
solution was diluted to 10 ml with 0.01 M hydrochloric acid. 
 
Sample Injection Procedure 
10 µl of filtered sample solution and standard solution were separately injected 
into HPLC system. The chromatogram was recorded and responses were measured for 
major peaks. 
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The content of Ondansetron in the powder mixture was calculated by using the 
following equation, 
 
Content of Ondansetron = Avg.Wt  
100
P
  
  weightSample
 weightStandard
  
area Standard
area Sample
  
 
Where, 
Avg. Wt - Average weight in mg 
 P - Purity of Ondansetron hydrochloride. 
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4.5.6.11. IN VITRO DISSOLUTION STUDIES
71
  
 
Dissolution Parameters 
Apparatus  : USP Dissolution apparatus, type I (Basket)  
Medium  : 500 ml of 0.1 M Hydrochloric acid 
RPM   : 50  
Temperature  : 37°C ± 0.5°C 
Sampling interval : 2, 4, 6, 8, 10 minutes 
Sample withdrawn : 5ml 
Wavelength  : 310nm 
Instrument : UV spectroscopy  
 
Preparation of 0.1 M Hydrochloric Acid 
Place 8.5 ml of concentrated hydrochloric acid into the 1000 ml volumetric 
flask and the volume were made up with de-mineralized water. 
 
Procedure 
The in vitro dissolution studies of Ondansetron HCl orally disintegrating 
tablets were performed using USP dissolution apparatus type 1(basket). The volume 
of dissolution medium (0.1M HCl) used was 500 ml and the temperature was 
maintained at 37°C±0.5°C. The speed of the basket was set at 50rpm. One tablet was 
placed in each jar of dissolution apparatus.  5ml of sample from each jar was 
withdrawn at every 2 minutes interval upto 10 minutes and same volume of 0.1M HCl 
was replaced to each dissolution jar, so that volume of dissolution medium was 
maintained to 500ml. Then the sample was filtered and diluted with 0.1M HCl and the 
amount of Ondansetron HCl released from ODT
S 
was determined 
spectrophotometrically at 310 nm using 0.1M HCl as blank. 
 
 
 
 
 
 
Chapter-4                                                                              Methodology 
 
S.B.C.P                           Department of Pharmaceutics Page 89 
 
4.5.6.12. STABILITY STUDIES
104
  
Stability of a formulation can be defined as the time from date of manufacture 
of the formulation until its chemical or biological activity is not less than a 
predetermined level of labeled potency and its physical characteristics have not 
changed appreciably or deleteriously.   
 
 Formulation and the development of a pharmaceutical product is not complete 
without proper stability analysis. It is carried out to assess the physical and chemical 
stability and safety use of the product.  The purpose of stability testing is to provide 
evidence on how the quality of a drug substance or drug product varies with time 
under the influence of a variety of environmental factors such as temperature, 
humidity and light, enabling recommended storage conditions, re-test periods and 
shelf lives. 
 
4.5.6.12.1 ACCELERATED STABILITY STUDIES 
 Generally, the observation of the rate at which the product degrades under 
normal room temperature requires a long time. To avoid the undesirable delay, the 
principles of accelerated stability studies are adopted by accelerating the parameters 
such as temperature, humidity and light.  
 
The International Council for Harmonization (ICH) guidelines titled “Stability 
testing of new drug substances and product” (QIA) describes the stability test 
requirements for drug registration application in the European Union, Japan and 
United States of America. ICH specifies the length of study and storage conditions. 
 Long –term testing: 25  2°C/60%  5% RH for 12 months. 
 Accelerated testing: 40  2°C/75%  5% RH for 6 months. 
 
Procedure 
       Stability studies were carried out optimized formulation at 25 2°C/60 5% RH 
and 40  2°C/75%  5% RH for (F-VII) for 3 months. The selected clear ALU-ALU 
packed formulations were stored at 25 2°C/60%  5% RH and 40 2°C/75% 5% 
RH for 3 months and their physical appearance, average weight, thickness, hardness, 
friability, disintegration test, in vitro dispersion time, fineness of dispersion, assay and 
in vitro drug release were evaluated at specified intervals of time(every month). 
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CHAPTER-5 
 
5. RESULTS AND DISCUSSION 
 
The present study was undertaken to formulate Ondansetron hydrochloride orally 
disintegrating tablets by direct compression method using three superdisintegrants such as 
croscarmellose sodium, crospovidone and sodium starch glycolate. The study was aimed to 
prevent inherent drawbacks associated with conventional tablets of Ondansetron 
hydrochloride such as risk of choking, bitter taste and difficult in swallowing by formulating 
Ondansetron hydrochloride ODT
S
. Preformulation studies were carried out before the 
formulation in which certain parameters were evaluated. A total of seven formulations were 
prepared to achieve rapid oral disintegration of Ondansetron hydrochloride (three trials by 
addition of mannitol anhydrous, three trials by sorbitol granular grade and one trial by both 
mannitol anhydrous and microcrystalline cellulose (MCC-112).  
 
The prepared blend of seven different formulations were evaluated for 
precompression parameters such as angle of repose, bulk density, tapped density, 
compressibility index and Hausner’s ratio. The prepared tablets were also evaluated for 
various post compression parameters like appearance, thickness, hardness, weight variation, 
friability, disintegration test, wetting time, water absorption ratio, in vitro dispersion time, 
fineness of dispersion, drug content and in vitro dissolution studies. 
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5.1 PREFORMULATION STUDIES 
5.1.1. ORGANOLEPTIC PROPERTIES 
The organoleptic properties of Ondansetron hydrochloride were presented in Table: 13 
 
Table: 13 Organoleptic Properties of Ondansetron HCl (API) 
Tests Specification Observation 
Color White White 
Odor Odorless Odorless 
Taste Bitter Bitter 
 
Discussion 
 The organoleptic properties like color, odor and taste of the API were evaluated. The 
color of Ondansetron HCl was found to be white or almost white powder, no characteristic 
odor was observed in the study and the taste was found to be bitter. Ondansetron 
hydrochloride showed similar color, taste and odor as per IP specification. 
  
5.1.2. SOLUBILITY TEST  
 The solubility profile of Ondansetron hydrochloride was presented in Table: 14. 
 
Table: 14 Solubility Analysis of Ondansetron HCl (API) 
Raw Material (API) Solubility 
Ondansetron HCl 
Sparingly soluble in water 
Sparingly soluble in ethanol 
Soluble in methanol 
 
Discussion 
The solubility studies of drug (API) revealed that Ondansetron HCl was sparingly 
soluble in water and ethanol and soluble in methanol. 
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5.1.3. DRUG - EXCIPIENTS COMPATIBILITY STUDIES 
 Compatibility studies were performed by preparing blend of different excipients with 
drug and stored at 40
O
C±2
O
C /75±5%RH for one month. The blends were evaluated for every    
15 days for changes like caking, liquefaction, discoloration and odor formation. The results 
were given in table: 15. 
 
Table: 15 Drug- Excipients Compatibility Study 
S. No. Composition Initial Period 
After 
15 Days 
After  
30 Days 
1 Ondansetron HCl 
White to off white 
powder with no 
characteristic odor 
NCC NCC 
2 Ondansetron HCl + Mannitol anhydrous NCC NCC 
3 Ondansetron HCl + Sorbitol granular grade NCC NCC 
4 
Ondansetron HCl + Microcrystalline 
cellulose (MCC-112) 
NCC NCC 
5 Ondansetron HCl + Sodium starch glycolate NCC NCC 
6 Ondansetron HCl + Croscarmellose sodium NCC NCC 
7 Ondansetron HCl + Crospovidone NCC NCC 
8 Ondansetron HCl + Methylparaben NCC NCC 
9 Ondansetron HCl + Propylparaben NCC NCC 
10 Ondansetron HCl + Sucralose NCC NCC 
11 Ondansetron HCl + Magnesium stearate NCC NCC 
12 Ondansetron HCl + Sunset yellow FCF Yellow color powder NCC NCC 
13 Ondansetron HCl + Strawberry flavor 
White to off white 
powder with 
strawberry  odor 
NCC NCC 
NCC: No Characteristic Change 
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Discussion 
 From the above drug excipients compatibility study, it was observed that there was no 
characteristic change found between the drug and excipients. Thus it was concluded that the 
excipients selected for the formulation were compatible with Ondansetron hydrochloride and 
suitable for formulation development.  
 
5.2 FT-IR SPECTRAL STUDIES 
 FT-IR studies of the pure Ondansetron, superdisintegrants and combination of drug 
and superdisintegrants containing highest proportion were carried out to found any 
interaction between drug and excipients used in the formulation. FT-IR study was performed 
using IR spectroscopy (SHIMADZU). The results are shown in fig: 6 to 12 and in            
table: 16 to 22. The comparison of FT-IR spectral data of drug with superdisintegrants was 
given in table: 23. 
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Fig: 6 FT-IR Spectrum of Pure Ondansetron Hydrochloride 
 
 
Table: 16 FT-IR Spectral Data of Pure Ondansetron Hydrochloride 
 
S.no Wave Number(cm
-1
) Functional Group 
1 3408 Broad band of bonded OH 
2 1637 C=O of aryl acids stretching  
3 1458 C=N stretching 
4 1420 Aromatic C=C stretching 
5 1083 C-N stretching 
6 754 CH3 angular 
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Fig: 7 FT-IR Spectrum of Croscarmellose sodium 
 
 
Table: 17 FT-IR Spectral Data of Croscarmellose sodium 
S.no Wave Number(cm
-1
) Functional Group 
1 3547 OH stretching 
2 2930 Aliphatic C-H stretching 
3 1646 C=O stretching 
4 1080 C-O stretching 
5 994 C-O-C group 
6 710 CH2 Alkane 
 
Chapter-5                                                                        Results and Discussion 
 
S.B.C.P                                        Department of Pharmaceutics Page 96 
 
 
Fig: 8 FT-IR Spectrum of Crospovidone 
 
 
Table: 18 FT-IR Spectral Data of Crospovidone 
 
S.no Wave Number(cm
-1
) Functional Group 
1 3448 OH stretching 
2 2953 Aliphatic C-H 
3 1657 C=O stretching 
4 1290 C-N stretching 
5 738 C-H methane 
6 651 CH2 group 
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Fig: 9 FT-IR Spectrum of Sodium starch glycolate 
 
 
Table: 19 FT-IR Spectral Data of Sodium starch glycolate 
 
S.no Wave Number(cm
-1
) Functional Group 
1 3282 OH bending 
2 1605 C=O stretching 
3 1159 C-O stretching 
4 767 C-C stretching 
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Fig: 10 FT-IR Spectrum of Ondansetron Hydrochloride + Croscarmellose sodium 
 
Table: 20 FT-IR Spectral Data of Ondansetron Hydrochloride + Croscarmellose 
sodium 
 
S.no Wave Number(cm
-1
) Functional Group 
1 3486 OH stretching 
2 3047 Aromatic C-H 
3 2942 Aliphatic C-H 
4 1638 C=O stretching 
5 1531 Aromatic C=C 
6 1082 C-N bending 
7 993 C-O stretching 
8 758 CH3 group 
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Fig: 11 FT-IR Spectrum of Ondansetron Hydrochloride + Crospovidone 
 
Table: 21 FT-IR Spectral Data of Ondansetron Hydrochloride + Crospovidone 
 
S.no Wave Number(cm
-1
) Functional Group 
1 3642 Aromatic C-H 
2 3485 OH bending 
3 2947 Aliphatic C-H 
4 1639 C=O stretching 
5 1531 C=C stretching 
6 1461 C=N stretching 
7 1082 C-N stretching 
8 1042 C-O stretching 
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Fig: 12 FT-IR Spectrum of Ondansetron Hydrochloride + Sodium starch glycolate 
  
Table: 22 FT-IR Spectral Data of Ondansetron Hydrochloride + Sodium starch 
glycolate 
 
S.no Wave Number(cm
-1
) Functional Group 
1 3486 OH bending 
2 3085 CH aromatic  
3 2942 Aliphatic CH 
4 1638 C=O stretching 
5 1531 C=C stretching 
6 1459 CH2 group 
7 1015 C-O stretching 
8 758 Aliphatic CH3 
 
 
 
Chapter-5                                                                        Results and Discussion 
 
S.B.C.P                                        Department of Pharmaceutics Page 101 
 
 
Table: 23 Comparative FT-IR Spectral Data of Drug and Superdisintegrants 
 
Compounds 
Functional Groups 
OH (cm
-1
) C=O (cm
-1
) C=C (cm
-1
) C-O (cm
-1
) 
Aliphatic CH3 
(cm
-1
) 
Drug 
(Ondansetron 
Hydrochloride) 
3408 1637 1420 1040 754 
Drug + CCS 3486 1638 1531 993 758 
Drug  + CP 3485 1639 1531 1042 758 
Drug + SSG 3486 1638 1531 1015 758 
 
Discussion 
FT-IR spectral studies indicated that the drug is compatible with all the excipients. 
The FT-IR spectrum of physical mixture showed all the characteristic peaks of Ondansetron 
hydrochloride, thus conforming that no interaction of drug occurred with the components of 
the formulation. 
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5.3 EVALUATION OF PRECOMPRESSION PARAMETERS 
 
5.3.1. MICROMERITIC PROPERTIES 
 The powder blends were evaluated for the following parameters such as angle of 
repose, bulk density, tapped density, compressibility index and Hausner’s ratio. The results 
were given below in Table: 24 
 
Table: 24 Precompression Parameters  
 
Formulation 
Code 
Angle of 
Repose (θ) 
Bulk 
Density 
(g/cm
3
)  
Tapped 
Density 
(g/cm
3
) 
Compressibility 
Index (%) 
Hausner’s 
ratio 
F-I  32
o
.11’ 0.562 0.690 18.55 1.22 
F-II 29
o
.09’ 0.640 0.745 14.09 1.16 
F-III 27
o
.06’ 0.305 0.351 13.11 1.15 
F-IV  29
o
.98’ 0.317 0.367 13.63 1.15 
F-V 26
o
.23’ 0.310 0.360 13.89 1.16 
F-VI 25
o
.09’ 0.318 0.378 15.87 1.18 
F-VII 22
o
.98’ 0.311 0.368 15.21 1.18 
 
Discussion 
The angle of repose of formulation F-I was found to be 32
o
.11’ which indicates good 
flow property. Angle of repose of all the other formulations were found to be between 22
o
.98’ 
to 29
o
.98’ which indicates excellent flow property. 
The bulk density was found to be between 0.305 to 0.640 g/cm
3
, the tapped density 
was found to be between 0.351 to 0.745 g/cm
3
, the compressibility index was found in the 
range of 13.11 to 18.55% and the Hausner’s ratio lies between 1.15 to 1.22. 
The above results in terms of micromeritic properties revealed that the flow property 
of formulation F-I was fair and other formulations were good.  
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5.4. EVALUATION OF ONDANSETRON HYDROCHLORIDE ODT
S 
5.4.1. POST COMPRESSION PARAMETERS
 
5.4.1.1. GENERAL APPEARANCE 
The general appearance of all formulations (F-I to F-VII) were examined and found as 
follows, 
 Color - Orange 
 Shape - Round 
 Surface – Smooth  
 Cracks, depressions, pinholes - Absent 
 The prepared tablets were evaluated for various post compression parameters. The 
results are presented in Table: 25 and 26. 
 
Table: 25 Post Compression Parameters 
Formulation 
Code 
Thickness 
(mm) 
Hardness 
(kg /cm
2
) 
Weight 
Variation (mg) 
Friability 
(%) 
F-I 3.20± 0.055 4.50± 0.32 142±1.25 0.24 
F-II 3.30± 0.010 4.50± 0.22 140±0.65 0.42 
F-III 3.20± 0.017 3.00± 0.27 140±0.46 0.50 
F-IV 3.40 ± 0.016 4.50± 0.21 143±0.89 0.46 
F-V 3.40 ± 0.020 4.50± 0.49 140±0.45 0.32 
F-VI 3.20± 0.062 3.50± 0.29 142±0.96 0.20 
F-VII 3.30± 0.018 3.00± 0.24 141±1.45 0.15 
Marketed 
sample 
2.90± 0.055 3.50± 0.32 140±0.89 0.26 
          All the values are expressed as mean± SD, n=3 
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Discussion 
The thickness of the tablets was measured and were found in the range between          
3.20  0.017 mm to 3.40 0.020mm. All the formulations possessed uniform thickness. 
The hardness of the tablets was measured and the values were found in the range 
between 3.00± 0.27 to 4.50± 0.49 kg/cm
2
. The prepared tablets possessed good mechanical 
strength with sufficient hardness. 
 All formulations of Ondansetron hydrochloride orally disintegrating tablets passed 
the weight variation test since the values are within the acceptable variation limit of the 
tablet. 
Similarly percentage friability values of the prepared Ondansetron hydrochloride 
orally disintegrating tablets showed less than 1% weight loss that is highly within the 
acceptable limit. Hence all the tablets passed the friability test. 
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Table: 26 Evaluation of Ondansetron Hydrochloride ODT
S 
 
Formulation 
Code 
Disintegration 
Test 
(Sec) 
Wetting 
Time 
(Sec) 
Water 
Absorption 
Ratio 
In vitro 
Dispersion 
Time (Sec) 
Fineness of 
Dispersion 
F-I 28±0.23 102±1.35 80.22±0.52 49±0.14 Passed 
F-II 24±0.12 90±1.19 85.36±0.58 38±0.12 Passed 
F-III 15±0.10 48±2.28 92.17±0.41 27±0.21 Passed 
F-IV 24±0.45 88±0.71 79.25±0.17 39±0.14 Passed 
F-V 23±0.58 81±0.10 87.12± 0.14 35±0.43 Passed 
F-VI 20±0.35 56±0.21 86.98±0.12 28±0.66 Passed 
F-VII 12±0.56 45±0.28 91.24±0.43 24±0.35 Passed 
Marketed 
sample 
17±0.32 54±0.45 94.31±0.21 27±0.26 Passed 
All the values are expressed as mean± SD, n=3 
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Discussion 
Disintegration time of Ondansetron hydrochloride orally disintegrating tablets ranges 
between 12 to 28 seconds. The acceptable disintegration time limit as per I.P is NMT 
30seconds. Formulation F-VII showed least disintegration time (12 sec) compared with all 
other formulations.  
Wetting time of Ondansetron hydrochloride orally disintegrating tablets were found to 
be in the range between 45 and 102 seconds. Formulation F-VII prepared by using 
crospovidone as superdisintegrant showed least wetting time (45 sec). 
Water absorption ratio of Ondansetron hydrochloride orally disintegrating tablets 
were found between 79.25 to 92.31. 
In vitro dispersion time of the Ondansetron hydrochloride orally disintegrating tablets 
were found between 24 to 49 seconds. Formulation F-VII showed rapid dispersion (24 sec) 
compared with all other formulations. 
In fineness of dispersion test, the dispersion of all the seven formulations passed 
through sieve #22 and passed the test. 
From the above results, it was concluded that the formulation F-VII showed better 
tableting properties compared to the other formulations and marketed formulation and was 
selected as the best formulation. 
 The in vitro dispersion time of the best formulation (F-VII) at various time 
intervals (0, 12, 18, 24 seconds) were shown in Fig: 13. 
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In Vitro Dispersion Time of Formulation F-VII at Various Time Intervals 
 
At 0 seconds                                                     At 12 seconds 
               
  
 
 
At 18 seconds                                                   At 24 seconds 
                
 
Fig: 13 In Vitro Dispersion of Ondansetron Hydrochloride Orally Disintegrating 
Tablets 
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5.4.2. ASSAY OF ONDANSETRON HCl BY HPLC METHOD
 
The assay was carried out by HPLC method as per the procedure given in 
methodology part. The HPLC chromatogram of Ondansetron hydrochloride standard and 
sample formulations were shown in fig no: 14 to 21 and table: 27. 
 
 
S. No. Drug  RT* Area Plate count Symmetry 
1 
Ondansetron 
HCl 
3.994 2825201 3959 0.88 
*RT-Retention Time 
Fig: 14 HPLC Chromatogram of Ondansetron HCl (Standard) 
 
 
S. No. Name RT* Area Plate count Symmetry 
1 
Formulation 
F-I 
3.969 2818015 3924 0.83 
*RT-Retention Time 
Fig: 15 HPLC Chromatogram of Formulation F-I 
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S.No. Drug  RT* Area 
Plate 
count 
Symmetry 
1 
Formulation 
F-II 
3.982 2832750 3943 0.83 
*RT-Retention Time 
Fig: 16 HPLC Chromatogram of Formulation F-II 
 
 
 
S.No. Drug  RT* Area Plate count Symmetry 
1 
Formulation 
F-III 
3.989 2824401 3999 0.83 
*RT-Retention Time 
Fig: 17 HPLC Chromatogram of Formulation F-III 
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S.No. Drug  RT* Area Plate count Symmetry 
1 
Formulation 
F-IV 
3.994 294208 4014 0.83 
*RT-Retention Time 
Fig: 18 HPLC Chromatogram of Formulation F-IV 
 
 
 
S.No. Drug  RT* Area Plate count Symmetry 
1 
Formulation 
F-V 
3.957 2833511 4364 0.82 
*RT-Retention Time 
Fig: 19 HPLC Chromatogram of Formulation F-V 
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S.No. Drug  RT* Area Plate count Symmetry 
1 
Formulation 
F-VI 
3.957 2818431 4509 0.82 
*RT-Retention Time 
Fig: 20 HPLC Chromatogram of Formulation F-VI 
 
 
S.No. Drug  RT* Area Plate count Symmetry 
1 
Formulation 
F-VII 
3.989 2824401 3999 0.83 
*RT-Retention Time 
Fig: 21 HPLC Chromatogram of Formulation F-VII 
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Table: 27 Assay of Ondansetron Hydrochloride Orally Disintegrating Tablets 
Formulation 
Code 
Limit (%) Assay (%) 
F-I 
90 to 110% 
99.50 
F-II 98.85 
F-III 99.75 
F-IV 99.52 
F-V 99.55 
F-VI 98.82 
F-VII 99.87 
Marketed sample 98.69 
 
Discussion 
The assay of Ondansetron hydrochloride orally disintegrating tablets were found in 
the range between 98.82 to 99.87 %. The acceptable limit of Ondansetron content as per I.P is 
90 to 110%. The results revealed that the assay of Ondansetron hydrochloride was within the 
acceptable limits. 
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5.4.3. IN VITRO DISSOLUTION STUDIES 
 The in vitro drug release of Ondansetron Hydrochloride ODT
S
 were given in 
table: 28 and fig: 22 
 
 
Table: 28 Comparative In Vitro Drug Release Studies of Ondansetron       
Hydrochloride ODT
S
    
                                 
Time 
(min) 
Percentage Drug Release (%) 
Formulation Code 
F-I F-II F-III F-IV F-V F-VI F-VII 
2 
20.58±   
0.48 
25.85± 
0.37 
31.48± 
0.55 
18.53± 
0.33 
22.43± 
0.31 
30.10± 
0.58 
35.30± 
1.18 
4 
32.23± 
0.70 
34.71± 
0.60 
42.62± 
0.55 
31.17± 
0.28 
31.54± 
0.52 
48.52± 
0.43 
54.15± 
0.61 
6 
41.63± 
0.59 
49.88± 
0.26 
61.54± 
0.20 
48.67± 
0.43 
46.64± 
00.6 
59.92± 
0.98 
72.28± 
0.24 
8 
65.99± 
1.23 
69.60± 
0.68 
79.56± 
0.44 
58.96± 
0.70 
62.82± 
0.28 
74.18± 
0.67 
85.61± 
0.52 
10 
72.30± 
0.16 
76.07± 
0.50 
84.34± 
0.09 
70.73± 
0.60 
73.18± 
0.07 
81.62± 
0.11 
99.85± 
0.07 
     All the values are expressed as mean± SD, n=3 
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Fig: 22 Comparative In Vitro Drug Release Profiles of Ondansetron Hydrochloride 
ODT
S
  
 
Discussion 
Ondansetron hydrochloride release was studied in 0.1M hydrochloric acid for up to 10 
minutes. The formulation F-I (sodium starch glycolate), F-II (croscarmellose sodium),               
F-III (crospovidone) were prepared along with mannitol as diluent and the formulation F-IV 
(sodium starch glycolate), F-V (croscarmellose sodium), F-VI (crospovidone) were prepared 
along with sorbitol as diluent. Formulation F-VII (crospovidone) was prepared with 
microcrystalline cellulose along with mannitol as diluent. 
The drug release of formulation F-I, F-II and F-III was found to be 72.30± 0.16 %, 
76.07± 0.50% and 84.34± 0.09 % at 10 minutes. The drug release of formulation F-IV, F-V 
and F-VI was found to be 70.73± 0.60 %, 73.18± 0.07 % and 81.62± 0.11 % at 10 minutes. 
The drug release of formulation F-VII was found to be 99.85± 0.07 % at 10 minutes. The 
acceptable in vitro dissolution limit is NLT 80% of drug release at 10 minutes. Formulation 
F-III, F-VI and F- VII passed the in vitro dissolution studies. The higher dissolution rates 
were observed in formulation F-III, F-VI and F- VII prepared using crospovidone as 
superdisintegrant which may be due to rapid disintegration and fine dispersion of particles 
formed after disintegration. Formulation F-VII prepared using crospovidone as 
superdisintegrant showed maximum drug release. This may be due to highly porous structure 
of the superdisintegrant with direct compressible vehicle (microcrystalline cellulose), which 
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facilitates faster water uptake and hence faster disintegration, easy breakdown of particles 
and rapid dissolution. 
The order of enhancement of the dissolution rate with various superdisintegrants was 
found to be CP>CCS>SSG. Formulation F-VII was observed as optimized formulation based 
on rapid disintegration time, wetting time, in vitro dispersion time and dissolution profile. 
 
5.4.3.1. COMPARATIVE DISSOLUTION STUDY OF MARKETED FORMULATION 
AND OPTIMIZED FORMULATION (F-VII) 
 The dissolution profile of optimized formulation (F-VII) was compared with marketed 
Ondansetron HCl orally disintegrating tablet. The comparative drug release profiles are 
shown in table: 29 and fig: 23. 
 
Table: 29 Comparative In Vitro Release Data of Ondansetron HCl Marketed Tablet and 
Optimized Formulation (F-VII) 
 
 
 
 
 
 
 
 
 
                     All the values are expressed as mean± SD, n=3 
 
 
 
 
 
 
Time 
(min) 
Percentage Drug Release (%) 
Formulation F-VII Marketed Formulation 
2 35.30± 1.18 20.29± 0.28 
4 54.15± 0.61 32.16± 1.01 
6 72.28± 0.24 54.57± 0.94 
8 85.61± 0.52 70.59± 0.51 
10 99.85± 0.07 82.52± 0.43 
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Fig: 23 Comparative In Vitro Drug Release Profile of Ondansetron HCl Marketed 
Tablet and Optimized Formulation (F-VII) 
 
Discussion 
 The percentage drug release of marketed sample and optimized formulation (F-VII) 
was found to be 82.52±0.43 and 99.85±0.07% at 10 minutes. 
 The drug release of optimized formulation of Ondansetron HCl orally disintegrating 
tablets was found to be greater than that of marketed product. The  percentage drug release was 
found to be increased by 17.33% at 10 minutes interval in optimized formulation compared to 
the marketed product. 
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5.4.4. STABILITY STUDIES 
                  The optimized formulation (F-VII) was selected for the stability study and 
stored at 25 2°C/60%  5% RH and 40 2°C/75% 5% RH for a period of three months. 
The tablets were evaluated for various parameters like physical appearance, average weight, 
thickness, hardness, friability, disintegration, in vitro dispersion, fineness of dispersion, 
dissolution and assay at every one month interval. The results are presented in                  
table: 30 and 31. 
 
Table: 30 Stability Data of Ondansetron Hydrochloride ODT
S
 Stored at                        
25 2°C/60% 5% RH (F-VII) 
S. 
No. 
Storage Conditions: 25 2°C/60% 5% RH 
Tests 
Initial 
period 
1
st
 month 2
nd
 month 3
rd
 month 
1. Physical appearance* Complies Complies Complies Complies 
2. Average weight (mg) 141.50  140.37  140.89  140.11 
3. Thickness (mm) 3.30  3.30 3.30  3.30  
4. Hardness (kg/cm
2
) 3.00 
 
3.00  3.00  3.00  
5. Friability (%) 0.15 0.17 0.25 0.22 
6. 
Disintegration test 
(sec) 
12  12  14  11  
7. 
In vitro dispersion 
time (sec) 
24  25  24  23 
8. 
Fineness of 
Dispersion 
Passed Passed Passed Passed 
9. 
In vitro drug release 
at the end of 10 min 
(%) 
99.85 99.82 99.76 99.70 
10. 
Assay 
(Limit: 90 to110%) 
99.87 99.82 99.75 99.72 
*Physical appearance: Pale orange, Uncoated, Round shaped tablets. 
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Table: 31 Stability Data of Ondansetron Hydrochloride ODT
S
 Stored at                         
40 2°C/75% 5% RH (F-VII)  
S. 
No. 
Storage Conditions: 40 2°C/75% 5% RH 
Tests 
Initial 
period 
1
st
 month 2
nd
 month 3
rd
 month 
1. Physical appearance* Complies Complies Complies Complies 
2. Average weight (mg) 141.50 140.97 142.37 141.28 
3. Thickness (mm) 3.30 3.36 3.30 3.32 
4. Hardness (kg/cm
2
) 3.00
 
3.00
 
3.00
 
3.00
 
5. Friability (%) 0.15 0.20 0.19 0.23 
6. 
Disintegration test 
(sec) 
12 12 10 08 
7. 
In vitro dispersion 
time (sec) 
24 24 24 23 
8. 
Fineness of 
Dispersion 
Passed Passed Passed Passed 
9. 
In vitro drug release 
at the end of 10 min 
(%) 
99.85 99.76 99.70 99.60 
10. 
Assay 
(Limit: 90 to110%) 
99.82 99.78 99.75 99.72 
*Physical appearance: Pale orange, Uncoated, Round shaped tablets 
 
Discussion  
 Stability studies revealed that there were no significant changes found in 
physical appearance, average weight, thickness, hardness, friability, disintegration test, in 
vitro dispersion test, uniformity of dispersion, dissolution and assay during the period of 3 
months even after stored at 25 2°C/60%  5% RH and 40  2°C/75% 5% RH. The study 
revealed that the formulation F-VII was stable even stored at 25 2°C/60% 5% RH and 40
 2°C/75%  5% RH for 3 months. 
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CHAPTER-6 
 
6. SUMMARY AND CONCLUSION 
 
The present study was undertaken to formulate Ondansetron hydrochloride 
orally disintegrating tablets by direct compression method using three 
superdisintegrants such as croscarmellose sodium, crospovidone and sodium starch 
glycolate. The study was aimed to prevent inherent drawbacks associated with 
conventional tablets of Ondansetron hydrochloride such as risk of choking, bitter taste 
and difficult in swallowing by formulating Ondansetron hydrochloride ODT
S
.  
A total of seven formulations were prepared to achieve rapid oral 
disintegration of Ondansetron hydrochloride (three trials by addition of mannitol 
anhydrous, three trials by sorbitol granular grade and one trial by both mannitol 
anhydrous and microcrystalline cellulose (MCC-112).  
The preformulation study of API such as organoleptic properties, solubility, 
compatibility study and FT-IR drug- excipients interaction study were carried out. 
The prepared blend were also evaluated for precompression parameters such 
as angle of repose, bulk density, tapped density, compressibility index and Hausner’s 
ratio. 
 The prepared tablets were evaluated for post compression parameters such as 
thickness, hardness, weight variation, friability, disintegration, wetting time and water 
absorption ratio, in vitro dispersion time, fineness of dispersion, assay and in vitro 
drug release. 
 
From the experimental results the following points can be summarized, 
 
 In the preformulation study Ondansetron HCl showed similar color, taste and 
odor as per the I.P specification. The results of drug excipients compatibility 
study showed that the excipients selected for the formulation were compatible 
with the API and suitable for formulation development. 
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 FT-IR spectral studies of pure drug and drug with excipients showed that there 
was no interaction between the drug and excipients used in the formulation. 
 The results of micromeritic properties indicates that the flow property of 
formulation F-I was fair and other formulations were good. 
 All formulations possessed uniform thickness. The prepared tablets also 
possessed good mechanical strength with sufficient hardness. 
 All formulations of Ondansetron hydrochloride ODTS passed the weight 
variation and friability test. 
 Disintegration time of Ondansetron hydrochloride ODTS were found between 
12 to 28 seconds. Formulation F-VII showed least disintegration time (12 sec) 
compared with all other formulations. 
 Wetting time and water absorption ratio of Ondansetron hydrochloride ODTS 
were found to be in the range between 45 to 102 seconds and 79.25 to 92.17 
respectively. Formulation F-VII prepared by using crospovidone as 
superdisintegrant showed least wetting time (45 sec) and good water absorption 
ratio among all formulations. 
 In the in vitro dispersion time evaluation, formulation F-VII showed rapid 
dispersion time (24 sec) compared with all other formulations. 
 All formulations of Ondansetron hydrochloride ODTS passed the fineness of 
dispersion test. 
 The assay values of Ondansetron hydrochloride tablets were found within the 
acceptable limits (98.82 to 99.87%).  
 In the in vitro drug release study, formulation F-VII prepared using 
crospovidone as superdisintegrant showed maximum drug release (99.85%) at 
the end of 10 minutes. 
 The order of enhancement of dissolution rate with various superdisintegrants 
was found to be CP>CCS>SSG. 
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 The obtained data suggested that the formulation containing crospovidone as 
superdisintegrant showed better disintegration time, in vitro dispersion, wetting 
time and in vitro drug release. 
 Hence formulation F-VII was considered as the optimized formulation based on 
rapid disintegration time, wetting time, in vitro dispersion and drug release. 
 Comparative study of optimized formulation (F-VII) and marketed product was 
carried out. The in vitro drug release of optimized formulation (F-VII) was 
rapid (99.85%) compared to the marketed product (82.52%) at 10 minutes. 
From the results, it was concluded that the formulation F-VII showed rapid 
drug release compared to the marketed product. 
 The stability study of optimized formulation (F-VII) indicated that there was no 
significant changes found in physical appearance, thickness, hardness, average 
weight, friability, disintegration, in vitro dispersion, fineness of dispersion, 
assay and in vitro drug release. The result showed that the optimized 
formulation (F-VII) was stable even after stored at 25 2°C/60%  5% RH and                  
40 2°C/75%  5% RH for a period of 3 months. 
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CONCLUSION 
 
 From the overall results, the study concluded that orally disintegrating tablets 
of Ondansetron hydrochloride could be successfully formulated by direct compression 
method using crospovidone as superdisintegrant, which could be a promising 
formulation to effectively treat nausea and vomiting caused by cytotoxic agent, 
thereby preventing inherent drawbacks associated with conventional tablets such as 
risk of choking, bitter taste and difficult in swallowing, also providing faster 
disintegration, rapid release, bypassing first pass effect, improve patient compliance 
and therapeutic effectiveness.  
 From all the above observation it was concluded that the formulation F-VII 
containing crospovidone as superdisintegrant along with mannitol and 
microcrystalline cellulose as diluent was found to be better one compared to the other 
formulations and satisfied the criteria for orally disintegrating tablets. 
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7. FUTURE PLAN 
 
Formulation (F-VII) may be further investigated for following studies: 
 
 Long term stability study as per ICH guidelines. 
 Scale up studies of the optimized formulation F-VII. 
 The treatment of nausea and vomiting caused by cytotoxic chemotherapy 
drugs using the developed tablet formulation. 
 Ondansetron hydrochloride orally disintegrating tablet formulations may 
be evaluated for various Pharmacokinetic parameters. 
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